The University of Maine

DigitalCommons@UMaine
Honors College
6-2019

Synthesis of a Fluorescently Tagged Bioactive Probe Specific to
Neutrophils in a Zebrafish Model
Sadie Xiaohua Novak

Follow this and additional works at: https://digitalcommons.library.umaine.edu/honors
Part of the Chemistry Commons

Recommended Citation
Novak, Sadie Xiaohua, "Synthesis of a Fluorescently Tagged Bioactive Probe Specific to Neutrophils in a
Zebrafish Model" (2019). Honors College. 560.
https://digitalcommons.library.umaine.edu/honors/560

This Honors Thesis is brought to you for free and open access by DigitalCommons@UMaine. It has been accepted
for inclusion in Honors College by an authorized administrator of DigitalCommons@UMaine. For more information,
please contact um.library.technical.services@maine.edu.

SYNTHESIS OF A FLUORESCENTLY TAGGED BIOACTIVE PROBE
SPECIFIC TO NEUTROPHILS IN A ZEBRAFISH MODEL
by
Sadie XiaoHua Novak

A Thesis Submitted in Partial Fulfillment
of the Requirements for a Degree with Honors
(Chemistry)

The Honors College
University of Maine
May 2019

Advisory Committee:
Matthew Brichacek, Assistant Professor of Chemistry, Advisor
Richard Brucher, Associate Professor of English
Brian Frederick, Associate Professor of Chemistry
Natalie Machamer, Lecturer of Organic Chemistry
Robert Wheeler, Associate Professor of Microbiology

© 2019 Sadie Novak
All Rights Reserved

ABSTRACT

Fluorescent bioimaging has proven to be a powerful tool in non-invasively studying
biological processes in living systems. One application of this technique is being used in a
transgenic zebrafish model to study the innate immune response to infection of Candida
Albicans. Methods utilizing genetic engineering, however, are limited by time constraints
that arise when having to depend upon the ability to modify genetics of the model. To
bypass these constraints, this project seeks to produce a modified version of a previously
developed biofluorescent probe, which was validated in a mouse model. The probe consists
of three components, a hexapeptide, a fluorophore, and a polyethylene glycol (PEG)
polymer. The peptide was found to bind to the formyl peptide receptors (FPRs) of the
neutrophils in mice. Synthesis of this peptide was accomplished using solid phase peptide
synthesis and standard Fmoc-chemistry. The peptide was purified via high performance
liquid chromatography (HPLC), and characterized via mass spectrometry and 1H NMR and
13

C NMR. The product had a yield of 9 mg. The PEG polymer serves to increase

bioavailability and was conjugated to the peptide in sodium borate acetonitrile buffer
system. This molecule was characterized via MALDI mass spectrometry and resulted in a
yield of 4.9 mg. Further studies will verify the successful conjugation of the fluorophore
to the PEG polymer. Once characterized, the probe will be validated through application
to an unmodified zebrafish model.
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CHAPTER 1: INTRODUCTION

The role of the innate immune system in the presence of infection has been of great
interest to researchers in recent years. Bioimaging is a technique that involves molecularguided imaging of living systems at the cellular level.1 It is unique in that it enables the
analysis of cellular interactions at the molecular level and is being developed to be utilized
in research and clinical settings for diagnostics and treatment of disease.2 Bioimaging is
powerful due to the nature in how it enables researchers to essentially “see” and visually
observe cellular events and interactions. Furthermore, this technique may be performed on
biological systems in vitr o as well as in vivo, allowing for visualization in real-time. It also
provides information concerning the localization and quantity of the molecules of interest.
As a result, bioimaging has further expanded possibilities in biological research by the level
of information it can provide researchers.
The hallmark feature of bioimaging is the probe that is used for visualization. The
probe is a molecule that is designed specifically for the cellular interaction of interest and
is modified to include a molecular component that will enable visualization, usually a
fluorescent dye or a radiolabel.1 Reflective of the vast diversity of cellular interactions that
occur in a living system as complex as the human body, a number of different probes have
been developed to investigate these interactions, showing the versatility of this technique.
One application of the bioimaging technique has been to investigate the role of the
innate immune system in the presence of infection.3 Currently, there are studies to
understand the mechanisms of the innate immune response in a host infected with the
microbe Candida Albicans (C. albicans).4 Currently, researchers are using a method of
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fluorescent imaging that involves use of a fluorescent transgenic zebrafish model to
visualize the cellular interactions of the zebrafish neutrophil. However, a bioactive probe
is of interest to provide an alternative synthetic approach to bioimaging these models, and
further understanding the role of the innate immune system in the presence of infection in
human systems.

1.1. General characteristics of the innate immune system and response in humans
Humans contain and carry a plethora of different microbes that reside on all surfaces of the
body. The body contains at least 10 times more bacterial cells than it does human cells.5
Many of these microbes thrive in colonies throughout the body and maintain a commensal
relationship with the host, and some others even share a mutualistic-type of relationship.
Infection occurs when a microbe enters the host organism and multiplies to a point of
overgrowth, and the number of organisms is no longer in a state of equilibrium with the
host.6 Disease differs from infection in that it affects a small percentage of infected people
and causes damage to cells of the body.5
In general, the immune system is comprised of many different cells that work alone
and together in different combinations against different types of attacks on the body.
Historically, the immune system was regarded as two systems, the innate response and the
adaptive response.7 Another subcategory is comprised of anatomical and physiological
barriers against foreign substances, pathogens, and any other cells that are not compatible
with the host organism. After the anatomical and physiological barriers were breached, it
was concluded that the innate immune response was the host organism’s first line of
defense against infection. The innate system was considered to be a non-specific, but
immediate response, and was overlooked by the next line of defense, the adaptive immune
2

response, which was considered to be a specific mode of defense and much more
sophisticated. However, in recent years, research has proven the importance of the innate
immune system through a greater understanding of its role in infection and disease.
When infection occurs, the innate immune response is activated by the recognition
of the microbes and danger signals that are released from host cells that have been
damaged.8 A hallmark of the innate immune system is its mediation via phagocytic cells,
such as macrophages and neutrophils. Understanding the differences, roles, and
mechanisms of these different cells are important to fully understanding the process of
innate immunity. Conveniently, the nature of these cells can be investigated through the
use of fluorescence bioimaging.
Neutrophils are of specific interest in studying host defense and innate immunity
response. These cells are major pathogen-fighting agents in the body.9 The ability to be
quickly recruited to sites of infection and inflammation, to recognize and phagocytose
microbes, and kill pathogens through phagocytic and cytotoxic mechanisms are hallmarks
of the neutrophils, and are characteristics that make the cell so remarkable. Additionally,
recent research has suggested that there is a line of communication between neutrophils,
macrophages, and adaptive immune system. Originally, it was thought that neutrophils
were only present during the acute stage of infection, but evidence shows that neutrophils
play a larger role in influencing the immune system.

1.2. General characteristics of bioactive peptides and their role in bioimaging
Bioactive peptides have been broadly defined as protein fragments that have a
positive or negative effect on body functions or conditions and may have an influence on
health.11 These molecules have been found to exist in all living systems, and play critical
3

roles in a variety of functions such as the immune response in the presence of infection and
the regulation of blood pressure and glucose levels.10 They are derived from a variety of
sources, such as food and bacteria, and a number of biological mechanisms have been
proposed in regards to these peptides’ roles in the human body systems (Figure 1.1).

Figure 1. 1 Several proposed biological mechanisms for different bioactive peptides, including anti-diabetes
effects, anti-obesity effects, and anti-inflammation effects [Adapted from Li, et al., 2017].10

These molecules are of interest for therapeutic targets, based on their binding
characteristics to specific protein receptors. Drug molecules are being developed which
utilize bioactive moieties to selectively deliver encapsulated drugs, by targeting the protein
receptors that may be found on the surface of the cell of interest.12 This same principle is
being adapted for molecular-guided imaging technique.

4

Figure 1. 2 A cartoon depiction magnifying the surface of a neutrophil and showing the transmembrane
formyl peptide receptors [Adapted from Tsai, et al., 2016].13

For this project, the specific binding function of bioactive peptides will be utilized
for targeting the neutrophil cells of the zebrafish model for imaging, but will be modified
to have molecules useful for fluorescent imaging techniques. On the surface of the
neutrophil cells are protein receptors called formyl peptide receptors (FPRs) (Figure 1.2).14
There are three known types of these receptors, FPR1, FPR2, and FPR3. These receptors
are part of a larger class of receptors called G-protein coupled receptors (GPCRs), which
are involved in the recruitment of neutrophils in inflammatory events. However, they can
also be repurposed as receptors to bind a bioactive peptide modified with a fluorescent tag
to image neutrophil interactions with high selectivity. Studies have shown that these three
receptors do not always bind the same ligands.15 This aspect could be useful in developing
a peptide designed to target a specific FPR.
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1.3. The transgenic model and its application to study a host-pathogen interaction
Candida Albicans (C. albicans) is the most abundant type of fungal species in the
human microbiota.6 These organisms typically colonize different areas of the body,
commonly the gastrointestinal and genitourinary tracts. In healthy individuals, the species
falls into the commensal-type relationship with its host. However, in some cases when
alteration has occurred to the host microbiota or when alteration has occurred in the host
immunity, overgrowth of C. albicans can occur. It is the overgrowth of the fungi that results
in a wide range of infections within the host, such as commonly known yeast infections
and diaper rash. C. albicans is of the few fungal species that is disease-causing in humans.
It is a microorganism of great interest due to its notoriety for forming biofilms on various
medical devices, which presents a challenge in clinical settings to prevent patient infection.
This organism alone accounts for 15% of nosocomial sepsis cases.16
The impact C. albicans has on human health has created a push to further
understanding the role of the innate immune system response in the event of infection.
Having knowledge of this response mechanism could provide insight for therapeutics and
drug development. The zebrafish model is one tool researchers have used to study the
mechanisms of a wide range of infections in a preclinical setting, including that of C.
albicans.8,4

6

Figure 1. 3 A timeline showing the three hallmark stages of zebrafish development [Adapted from Masud,
et al., 2017]8

The zebrafish is an efficient model for a number of reasons. Similar to humans, the
immune response in zebrafish is a cooperative function between the innate and adaptive
immune systems. Further, the adaptive immune response in zebrafish matures much later
than the innate, thus zebrafish larvae are a prime candidate for studying innate immunity
in separation from the adaptive immune system (Figure 1.3). There is a window in which
the organism has not developed an adaptive immune response. Development of the
adaptive immune system is indicative by the presence of T cells.
Another major benefit of using zebrafish is the optimized optical accessibility the
specimen provides as a result of its transparent tissues. Finally, zebrafish embryos are
readily and easily colonized by commensal flora that are commonly found on surfaces of
the human body. Over the past decade, embryonic, larval, and adult zebrafish have been
used in a range of models to study the complexities of immune response.8
Another important aspect of the zebrafish model is the availability of genetically
engineered specimen which have been altered to express fluorescently actively proteins.
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The genome of the model of interest in this research project has been transformed to include
either the mpx:GFP or mpx:mCherry transgene.

4

In essence, the myeloperoxidase

promoter is included in the organism’s genome, which promotes the neutrophil-specific
expression of either the proteins green fluorescent protein (GFP) or the mCherry protein.
These proteins absorb and emit light at different wavelengths, but both within the visible
range, allowing for fluorescent imaging studies to be performed to visualize the cellular
interactions of the neutrophils. Furthermore, the wavelengths at which these proteins
fluoresce differ enough from the wavelengths that cause macrophages to fluoresce, which
ensures the ability to selectively visualize neutrophil cells.
While a useful method for imaging cellular interactions of neutrophils, this method
is tedious in its reliance on genetics. In the event that a fishline lacks the promoter necessary
to expresses fluorescently active proteins, the issue may be remedied by crossing fishlines.
However, the amount of time necessary to produce a functional model is costly to the flow
of research and is a disadvantage to this means of imaging. A synthetic alternative that can
be introduced to the zebrafish model endogenously is of interest in order to remove the
time hindrance associated with current methods while maintaining imaging functionality.
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1.4 Current bioactive probes designed to target study of the innate immune system
As previously discussed, a number of bioactive probes have been developed for use
in bioimaging techniques. One such probe was developed by a research group at the
University of Virginia that targets the FPRs on the surface of neutrophil cells in mice.17
This probe consisted of three components, a bioactive peptide, a polyethylene glycol (PEG)
polymer, and a Cyanine 7 fluorophore (Figure 1.4).

(a)

(b)
Figure 1. 4 (a) Hybrid structure of the bioactive probe developed by Xiao, et al [Adapted from Xiao, et al.,
2010].17 The complex includes a short hexapeptide capped with a cinnamoyl, cFLFLFK, a polyethylene
glycol (PEG) polymer and a Cyanine 7 fluorophore. (b) A graphical depiction of a bioactive probe developed
to selectively target the FPRs on the neutrophils in mice [Adapted from Riedel, 2013].18

Because the functionality of the bioactive probe depends solely on the bioactive
peptide that serves as the foundation, design of the bioactive peptide is important when
developing imaging probes. Figure 1.5 compares a few known ligands that have binding
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affinities FPRs (a) to the structure of the peptide designed for use as a bioactive probe
specific to mouse neutrophils.

(a)

(b)
Figure 1. 5 (a) Some known N-formylated ligands with binding affinities for FPRs [Adapted from Ye, et al.,
2017].15 (b) Structure of the target bioactive peptide, cFLFLFK.
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One similarity between some of the known ligands and the target molecule is the
presence of phenylalanine residues and leucine residues (Figure 1.5a in purple and yellow,
respectively). Another element in peptide ligands for FPRs are the presence of Nformylated methionine residues.19 The mechanism of this binding event is not clear, but
studies have shown that N-formylated peptides with a methionine residue at the the Nterminus commonly act as ligands to FPRs. The peptide highlighted in purple has a
methionine residue at the N-terminus and has been formylated (Figure 1.5a). The target
peptide (Figure 1.5b) is not formylated, nor does it include a methionine residue. However,
the cinnamoyl cap on the target peptide may mimic the effects of the N-formylated
methionine residue, in that it promotes binding to the FPR. It may also increase antagonistic
characteristics of the peptide, so that it binds to the FPR but does not result in signal
transduction. In essence, the peptide would have similar binding affinities, but the
neutrophil would not recognize the peptide as a recruiting molecule to elicit an immune
response against the peptide.
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Figure 1. 6 Overview of solid phase peptide synthesis using standard Fmoc-chemistry to produce the peptide
cFLFLFK.

For synthesis of the bioactive probe, first the peptide was produced via automated
solid phase peptide synthesis using standard Fmoc-chemistry.20 In solid phase synthesis,
there are two main steps that make up one coupling cycle of an amino acid fragment (Figure
1.6). The first step involves the removal of a protecting group, fluorenylmethyloxycarbonyl
(Fmoc), from the terminal amine of the peptide chain. In the Figure above the Nα that is
deprotected is the amine on the terminal end of the solid support (denoted as PS). In
subsequent coupling cycles, the amine to undergo deprotection will be a part of the peptide
backbone. This functional group is used to control the reactivity of the terminal amine
throughout reactions and reduces the likelihood of a doubling coupling event to occur
throughout the synthesis.21 Another protecting group, tert-butyloxycarbonyl (Boc), is used
to control the reactivity of the terminal amine of the lysine residue side chain, so to prevent
side chain reactions from occurring.22
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The use of protecting groups for Nα-amino protection is an important feature in
solid phase peptide synthesis techniques.21 The Fmoc group replaced the previously
preferred Boc group due to the milder conditions necessary for removal of the Fmoc group.
Deprotection of Fmoc requires a mild base, such as 4-methylpiperidine, whereas the Boc
group becomes labile in acidic conditions. The milder conditions allowed for the
elimination of repetitive acidolysis steps and the final strong acidolysis step which were
hallmarks of solid phase synthesis that used Boc group for Nα protection. This
characteristic is also more compatible with peptides that are susceptible to acid-catalyzed
side reactions, making the Fmoc compound a more efficient protecting group. However,
the compatibility between these two molecules based on their stabilities in different
conditions (basic/acidic) allows for selective deprotection of Nα-amino groups and
selective protection of reactive side chains throughout the synthesis of the peptide.
After deprotection, the first amino acid residue may be loaded onto the resin in the
next step. A coupling agent is used, 2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3tetramethylaminium hexafluorophosphate (HCTU), to activate the carboxylic acid of the
incoming amino acid fragment. Then the carboxylic acid donates the acyl group, which
forms the peptide bond. The peptide bond presents a nucleophilic attack on the α-amino
group of another amino acid.22 The incoming amino acid residue is also protected with an
Fmoc group, so to load the next amino acid the cycle begins again with removal of the
Fmoc group. Upon completion, the peptide can be released from the solid support under
strong acidic conditions. This step also globally deprotects the Boc-protected sidechains.
Stepwise, peptides can be synthesized from the C to the N terminus using N𝛼-protected
amino acids.23
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The modification to the peptide to include a PEG polymer was found to be
necessary to increase the bioavailability of the peptide.17 The peptide is composed of
largely non-polar amino acid residues (phenylalanine and leucine), further it is capped with
the cinnamoyl group at the N-terminus and the C-terminus has been functionalized with an
amide, rather than the typical carboxylate group. As a result, the peptide is highly
hydrophobic and its ability to remain in biological systems proved itself a challenge. A
PEG polymer of 3.4 KDa (76 repeat units) was determined to be a sufficient length to
increase the bioavailability and ensure the peptide could exist in aqueous environments
(i.e. when injected into the bloodstream if a mouse model). This molecule was attached to
the terminal amine of the lysine residue side chain through a conjugative addition reaction
in a 0.1 M acetonitrile sodium borate buffer system (pH 8.5).
The selection of the Cyanine 7 (Cy7) fluorophore was based on its emission
wavelength, 800 nm, which is in the near-infrared region (NIR). This was necessary due to
the application of the probe to a mouse model. At the NIR region, mammalian tissue has
low absorbance, thus the signal could better penetrate through the tissue. Fluorophores
chosen in the visible range would be difficult to visualize. This compound was conjugated
to the terminal amine of the PEG76 molecule using similar conditions to attach the PEG
polymer to the peptide.
The completed probe was synthesized using the methods previously described. In
addition to the target molecule, a series of derivatives were produced as well, with slight
modifications made. These modifications included varying lengths of the PEG polymer,
complete removal of the PEG polymer, and conjugation of the fluorophore to different
functional groups on the peptide and peptide-PEG molecule. The set of these bioactive
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probes were validated using a mouse model, and it was determined that the most effective
probe included the peptide, PEG76 polymer, and fluorophore conjugated to the PEG76
polymer.

Figure 1. 7 Representative image taken using NIR fluorescence imaging of mouse models 3 hours postinjection with the bioactive probe. Normal group (a); blocking group (b) pre-injected with a non-fluorescently
active bioactive probe before injection with bioactive probe [Adapted from Xiao, et al., 2010].

Specificity tests of the probe were performed on a mouse model. Acute
inflammation was induced by a topical application of phorbol myristate acetate (PMA) to
the left earlobes of the mice. This caused ear dermatitis, which ultimately promoted the
migration of neutrophils to the afflicted area. The fluorescent bioactive probe was injected
into the mouse model via a tail vein, and in vivo NIR fluorescence imaging was performed.
In models injected with the probe, fluorescence intensities were recorded at higher levels
than the control, suggesting high binding affinity for the FPRs on neutrophil cells.
Specificity experiments were conducted as well by pre-injecting mice with a nonfluorescent peptide one hour before injecting the specimen with the fluorescent probe. It
was expected that the models pre-injected with blocking agents would not show high
neutrophilic activation or accumulation under fluorescence studies if the bioactive peptide
was selective for FPRs. Comparative analysis showed lower fluorescence intensities in the
15

blocking group than in the normal group (Figure 1.7), suggesting that the probe has high
specificity for FPRs. The group concluded that a potential probe was synthesized for NIR
fluorescence bioimaging specifically targeted towards neutrophilic activation and
accumulation.17 This probe is available for commercial purchase.16 However, the
attachment of only the Cy7 fluorophore limits the range of use for the tool. Bioactive probes
such as the molecule developed for use in a mouse model that could be modified with a
range of fluorophores would increase the versatility of the probe and widen the possibilities
for bioimaging techniques.

1.5. Synthetic strategies to reproduce bioactive probe cFLFLFK-PEG76-fluorophore

Figure 1. 8 Chemical structures of various platforms of organic fluorescing molecules. The color of each
molecules loosely represents the color it emits.2

Due to the established superiority of the zebrafish model and the heightened interest
and importance of fluorescence bioimaging, there is a demand for the development of
bioactive probes that can be utilized for bioimaging studies. These probes are attractive
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based on the modes in which they are endogenously introduced to the model. There is a
movement towards developing new, novel fluorescent probes and biosensors that are a
hybrid between organic fluorescent molecules and synthetic molecules, reflective of the
probe developed by Xiao, et al.17 A host of different organic fluorescent molecules have
been discovered and reported to emit a range of different colors and have become
commonly used organic molecules in fluorescent imaging (Figure 1.8).2 The bright and
photostable dyes with red to near-infrared (NIR) fluorescence are highly attractive choices
for in vivo imaging in living systems because tissue is transparent in this wavelength
region. Cyanine dyes (Figure 1.8e) have been modified and adapted to accommodate this
demand. Fluorescein (Figure 1.8b) and rhodamine (Figure 1.8c) are the mostly commonly
used molecules for labelling or as probes for bioimaging.
The fluorescein and rhodamine dyes are also analogous to the GFP and mCherry
proteins previously discussed. These small molecules have potential to be incorporated into
a synthetic peptide targeting FPRs and replace the need for transgenic zebrafish models
used for studies of host-pathogen interactions in the presence of infection. Furthermore, as
there is a wide variety of known fluorophore molecules, there is potential to create a library
of probes that would increase the versatility of bioimaging of zebrafish models for
infection.
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1.6 Thesis Project Overview

Figure 1. 9 Structure of the target molecule of interest, cFLFLFK-PEG76-5(6)-ROX. The attached
fluorophore is a 5(6)-ROX, a derivative of the rhodamine class. This particular derivative is analogous to that
of the mCherry protein.

Synthesis of a bioactive probe for use in a zebrafish model to study host-pathogen
interactions was conducted using similar methods previously discussed. The target
molecule consisted of a bioactive peptide, PEG polymer, and small molecule fluorophore
(Figure 1.9). The short hexapeptide capped with a cinnamoyl, cFLFLFK, was produced
using solid phase peptide synthesis procedures. Both manual and automated methods were
investigated for production of the peptide. The addition of a PEG polymer was done
76

through bioconjuation in a buffer system. The fluorophores of interest were chosen based
on their similarities in characteristics to the current proteins encoded in transgenic zebrafish
models. A 5(6)-ROX fluorophore was chosen as the synthetic alternative to the mCherry
protein. It will be attached to the peptide-PEG complex through bioconjugation. After the
76

completion of each component (peptide, peptide-PEG , peptide-PEG -fluorophore),
76

76

purification was performed via high performance liquid chromatography (HPLC) and size
exclusion chromatography. Characterization studies were performed for each molecule
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with mass spectrometry, 1H NMR, 1C NMR, and UV-vis analyses. Once the target
molecule is completed, validation of the probe will be confirmed through application to an
unmodified zebrafish model.
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CHAPTER 2: EXPERIMENTAL

2.1. Materials and general considerations
All chemicals were available from commercial suppliers and did not undergo any
purification or altering unless specified. For automated peptide synthesis an AAPPtec
automated peptide synthesizer was used, and all reactions were run at room temperature
under N2. Analytical to semi-preparative high-performance liquid chromatography
(HPLC) was performed with a Gilson GX-271 liquid handler and a Gilson 322 pump. A
Kintex 5 µm EVO C18 100Å 4.6 x 150 mm column and Kinetex 5 µm EVO

C18 100Å 21.1 x 150 mm column were used for analytical and preparative purposes,
respectively. Data was rendered in Trilution LC software. Products were characterized by
1

H and

13

C NMR, liquid chromatography/mass spectrometry (LC/MS), matrix assisted

laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) and UVvis analysis. A Varian UNITY INOVA 400 MHz instrument was used to obtain 1H and 13C
NMR data. An Agilent 1100 series HPLC coupled with a diode array detector (DAD,
model G1315A) and a mass selective detector (MSD, model G2445A) operating in
electrospray ionization (ESI) was used to collect LC/MS data. A Bruker Daltonics
UltrafleExtreme MALDI TOFTOF instrument was utilized to collect MALDI-TOF MS
data. A Beckman DU 7500, Diode Array UV-vis spectrophotometer was used for UV-vis
analysis. A SpectraMax i3x UV-vis spectrophotometer was also used for UV-vis analysis.

20

2.2. Synthesis of hexapeptide, cFLFLFK-NH2, via solid phase peptide synthesis
using manual coupling techniques

1
2

3

5

4

Scheme 2. 1 Overview of synthesis of hexapeptide, cFLFLFK, with solid phase peptide synthesis using
standard Fmoc chemistry.

2.2.1. Preparation of Resin
The target peptide, a hexapeptide, cFLFLFK-NH2, was synthesized using a
modified procedure published by Xiao, et al13. To a polyprep column (BioRad), 0.1 g of
Fmoc-PAL-AM resin (0.5-0.8 mmol/g, EMD Milipore) was added. To prepare the solid
support, the resin was swelled by adding 2 mL of dry dichloromethane to the polyprep
column and then the column was agitated in an incubator at 190 rpm and room temperature.
After 1 hour, the dichloromethane was eluted, and the resin was washed with 2 mL of DMF
three times.
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2.2.2. Removal of Fmoc protecting group
For removal of the Fmoc group, a solution of 20% 4-methyl piperidine was
prepared in an inert environment and stored in a flame-dried 40-mL vial. Then 8 mL of the
prepared solution was added to the polyprep column containing the swelled resin and the
column was agitated in an incubator at 190 rpm, at room temperature, for 1 hour. The 20%
4-methyl piperidine solution was then eluted, and the resin was washed with 10 mL of
DMF, three times.

2.2.3. Elongation of peptide
For coupling of the first amino acid, an Fmoc-protected lysine, a coupling cocktail
was prepared by dissolving 0.281 g of Fmoc- Lysine (0.6 mmol), 0.248 g of O-(6Chlorobenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HCTU;
0.6 mmol), and 0.157 mL of diisopropylethylamine (DIPEA; 0.9 mmol) in 1 mL of DMF.
The solution was immediately transferred to the polyprep column, and the reaction was
agitated in an incubator at 190 rpm, at room temperature, for 1 hour. Once complete, the
coupling cocktail was eluted, and the resin washed with 10 mL of DMF three times.

2.2.4. Monitoring of reaction progress via UV-vis spectroscopy
To monitor the progress of the coupling reaction, 8 mL of DMF was added to the
column. The column was briefly shaken, to evenly disperse resin, and then 20 µL aliquot
of the solution was reserved and transferred to a 7 mL vial. The resin was dried under
vacuum to remove DMF. Then 3 mL of the 20% 4-methylpiperidine was added to the vial,
and the resin was agitated in an incubator at 190 rpm for about 20 minutes. Then a UV-vis
reading was taken at 290 nm against a blank of 20% 4-methyl piperidine.
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For the coupling of the subsequent amino acids, the previously described procedure
for deprotection of the Fmoc group and the coupling of the activated amino acid was
followed (Sections 2.2.2 and 2.2.3.). After each coupling reaction (described in section
2.2.3), loading was monitored via UV-vis.

2.2.5. Coupling of cinnamoyl cap
To cap the peptide with a cinnamoyl group, the Fmoc group was first removed from the
terminal amino acid (phenylalanine) following the previously described methodology. A
coupling cocktail was similarly prepared by dissolving 0.089 g cinnamic acid (0.6 mmol),
0.248 g of HCTU (0.6 mmol), and 0.157 mL of DIPEA (0.9 mmol) in 3 mL of DMF. The
solution was immediately transferred to the polyprep column and the reaction was agitated
in an incubator at 190 rpm, at room temperature, for 20 hours. At this point, the plastic
polyprep column, originally clear and colorless, was stained a dark brown, and the eluent
also a dark brown color. A pale brown colored sediment formed in the bottom of the
column. The resin was separated from the layer of sediment by adding DCM to the column
and collecting the top layer that formed, which contained only resin. The resin was then
washed with 5 mL of DCM three times.

2.3. Synthesis of peptide cFLFLK via automated synthesis
This procedure followed for manual coupling was adapted for synthesis of the
peptide using an automated peptide synthesizer. In set-up for this reaction, a solution of
20% piperidine in DMF was prepared, 0.5 M solutions of the amino acids were prepared,
0.5 M solution of HCTU was prepared, and a 0.75 M solution of DIPEA was prepared. To
the synthesizer 0.050 g of PAL-AM resin was added, and swelled in the peptide
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synthesizer, in DCM for 1 hour then washed with DMF three times before deprotection
and coupling proceeded.
For deprotection, 2.0 mL of 20% 4-methylpiperidine was transferred to the resin,
and the resin was incubated and shaken for 1 hour. Then the resin was washed with DMF
3 times. Then the instrument delivered 0.7 mL of 0.5 M Fmoc-protected amino acid
solution, 1 mL of 0.5 M HCTU, and 1 mL of 0.75 mL of DIPEA to the resin. The resin
was incubated and shaken for 1 hour, then washed with DMF 3 times, and the deprotection
and coupling cycles would begin for the next amino acid.
After the final coupling of the last phenylalanine residue, before removing the final
Fmoc group, the resin was washed a final time and then dried under N2 on the instrument.
The dried resin was transferred to a polyprep column, and the final deprotection and
coupling with the cinnamic acid was carried out following manual coupling procedures.

2.4. Cleavage of peptide from PAL-AM resin

6

2

7

Scheme 2. 2 Cleavage of synthesized peptide, cFLFLFK, from solid support using an 18:1:1 solution of
TFA, water, and triisopropylsilane.

To remove the synthesized peptide from the solid support after both manual
coupling and automated synthesis methods, the resin was first dried under a stream of N2
gas for 1 hour. Then a cleavage cocktail was prepared by combining 4.5 mL of TFA, 0.25
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mL of water, and 0.25 mL of triisopropylsilane (TIPS). The solution was immediately
transferred to the polyprep column containing the loaded resin. The reaction was agitated
in an incubator at 190 rpm, room temperature, for 1 hour. Then the solution was eluted and
collected in a 20 mL vial. The TFA, water, and TIPS solution was removed via a rotary
evaporator and dried under vacuum.

cFLFLFK

Minutes

Figure 2. 1 Analytical HPLC trace for purification of peptide cFLFLFK. Stationary phase: C18; mobile phase
water:acetonitrile, 30-70%, over 10 minutes. UV-vis detected at 254 nm and 280 nm. The peak retained at
4.5 minutes was collected characterization.

The product was purified via high-performance liquid chromatography (HPLC).
First analytical HPLC was performed, and UV-vis measurements were recorded at 254 nm
and 280 nm to optimize conditions. It was determined that at 30-70% water to acetonitrile,
over 10 minutes, the product was retained on the column for 4.5 minutes (Figure 2.1). The
product was then purified with preparative HPLC.
For manual coupling methods, the yield was 9 mg (9.52 µmol, 38%) of product.
For automated synthesis methods, the yield was 5.9 mg (6.25 µmol, 25%) of product. Using
HPLC, the retention time of cFLFLFK-NH2 was 4.5 minutes. The compound produced
using manual coupling procedures was characterized with LC/MS and 1H NMR and
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13

C

NMR. The solvent used was methanol-D. The mass of the product was calculated to be
944.5 g/mol. Results from the LC/MS showed that the product was 944.3 g/mol.
13

C NMR (101 MHz, CD3OD) δ 175.33 (s), 174.42 (s), 174.08 (s), 173.91 (s), 173.20 (s),

172.27 (s), 168.22 (s), 141.74 (s), 137.31 (d, J = 4.7 Hz), 136.62 (s), 134.75 (s), 130.24 –
129.66 (m), 128.32 (t, J = 55.2 Hz), 126.70 (s), 119.81 (s), 57.20 (s), 55.77 (d, J = 28.0
Hz), 53.84 (s), 53.26 (s), 52.81 (s), 40.02 (s), 39.50 (d, J = 16.9 Hz), 36.98 (s), 36.52 (s),
30.68 (s), 26.50 (s), 24.51 (d, J = 15.0 Hz), 22.20 (d, J = 23.5 Hz), 20.63 (d, J = 24.9 Hz).
1

H NMR (400 MHz, CD3OD) δ 8.64 – 8.55 (m, 8H), 8.64 – 8.31 (m, 36H), 8.10 (s, 5H),

7.95 – 7.77 (m, 41H), 7.66 – 7.46 (m, 40H), 7.46 – 7.32 (m, 36H), 7.32 – 6.73 (m, 158H),
6.72 (s, 9H), 4.87 (s, 307H), 4.44 (dd, J = 46.6, 39.2 Hz, 50H), 4.15 (dd, J = 15.3, 10.3 Hz,
23H), 3.37 – 3.20 (m, 107H), 3.19 – 3.00 (m, 44H), 3.00 – 2.21 (m, 92H), 2.02 (s, 5H),
1.88 (s, 9H), 1.71 (d, J = 9.6 Hz, 14H), 1.64 – 1.33 (m, 93H), 1.27 (d, J = 7.4 Hz, 13H),
1.11 (s, 6H), 0.96 – 0.74 (m, 104H).
2.5. Synthesis of peptide cFLFLFK-PEG76-NH2

8

6

9

Scheme 2. 3 Conjugation of polyethylene glycol polymer (PEG76) in a 0.1 M acetonitrile sodium borate buffer
of pH 8.5.
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For the conjugation of the polyethylene glycol molecule to the ω-NH2 of the lysine
residue, a procedure previously published by Zhang, et al. was followed20. In a 7 mL vial,
3.2 mg of peptide cFLFLFK-NH2 and 12.6 mg of tert-Boc-PEG-NHS (PEG76, MW-3400
Da; Laysan Bio Inc.) was dissolved in a 1:1 mixture of acetonitrile and sodium borate
buffer (0.1 M, pH 8.5), at 4°C or 24 hours. The reaction was monitored via analytical HPLC
(Figure A1). The stationary phase was a C18 column and the mobile phase was
water:acetonitrile (50-80%). Absorbance was measured at 215 nm and 254 nm. The
product was then purified via preparative HPLC using the conditions optimized in
analytical experiments and characterized via mass spectrometry (MALDI-TOF). The
calculated mass of the compound was 4489.6 g/mol. The experimental mass of the
compound was found to be 4511.9 g/mol.
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2.6. Conjugation of fluorophore, 5(6)-ROX NHS ester

10

9

11

Scheme 2. 4 Conjugation of 5(6)-ROX NHS ester fluorophore in a 0.1 M sodium bicarbonate buffer of pH
8.5.

2.6.1. Conjugate addition of 5(6)-ROX NHS ester
For the conjugation of the 5(6)-ROX NHS ester fluorophore, an adapted protocol
was used previously published by the manufacturer.24 In a 7-mL vial, covered completely
in aluminum foil, 2.8 mg of 5(6)-ROX NHS ester (3.48 µmol, 8 equivalents) were dissolved
in 1/10th of the reaction volume of DMSO (0.1 mL). In separate 7-mL vial, 1.9 mg of
cFLFLFK-PEG76-NH3+ compound was dissolved in 9/10th of the reaction volume of 0.1 M
sodium bicarbonate buffer (pH 8.5; 0.9 mL). The reaction was run for 12 hours at room
temperature. The reaction was monitored via HPLC. The stationary phase was a C18
column, and the mobile phase was water:acetonitrile (30-70%).
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2.6.2. Purification of cFLFLFK-PEG76-5(6)-ROX via size exclusion chromatography
Before purification, the product was condensed using rotary evaporation until about
0.1 mL of solvent remained. Solid precipitate formed, and 0.8 mL of distilled water was
added to the reaction vessel to re-dissolve product. Then the product was purified using
size exclusion chromatography on a Sephadex G-25 column. The Sephadex G-25 media
was pre-swelled in distilled water and then packed into a 4.5 cm tall column with diameter
2 cm. The column was equilibrated with distilled water. Then half of the solution
containing product (about 0.5 mL) was loaded onto the column. Over and hour and a half,
19 1-mL fractions were collected in 1.5-mL microcentrifuge tubes. The first 10 fractions
that eluted from the column were clear and colorless. The subsequent fractions were still
clear but were a pink hue that gradually intensified and then weakened again.
The fractions were analyzed via UV-vis spectroscopy. A plate was prepared with
100 µL of each fraction collected. A full absorbance spectrum was measured for each
fraction against a blank of distilled water. Based on this analysis, fractions 4-10 and then
fractions 11-17 were combined and condensed for further study. Instead of using a plate
reader, the samples scanned in a quartz cuvette against a blank of distilled water. Then the
sample containing fractions 11-17 was analyzed via mass spectrometry (MALDI-TOF
MS).
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CHAPTER 3: RESULTS & DISCUSSION

Part I

Part II

Part III

Figure 3. 1 Structure of overall target molecule, cFLFLFK-PEG76-5(6)-ROX. This is a bioactive,
fluorescently tagged peptide modified with a polyethylene glycol (PEG76) polymer. Synthesis of the
molecule was divided into three parts.

The target bioactive probe is of interest due to previous studies determining that
this peptide has a specific binding affinity to the formyl peptide receptors found the surface
of neutrophils in mice.17 This binding affinity provides researchers with a method to attach
small molecules, such as fluorophores, to the neutrophils. As a result, researchers are
enabled to visualize cellular interactions of the neutrophils at the molecular level.
Furthermore, these fluorescent imaging studies utilizing the bioactive probe may be
performed in vivo, as it is biologically relevant to living systems.
The target molecule in this study was a short hexapeptide, FLFLFK, capped with a
cinnamoyl, that was modified with the addition of a PEG76 polymer and tagged with a
fluorophore (Figure 3.1). The synthetic route was divided into three parts. First the peptide
capped with the cinnamoyl was to be synthesized. This molecule was targeted based on its
binding affinity to the formyl peptide receptors on the neutrophils in a mouse model. Then
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the PEG76 polymer could be conjugated to the peptide. The addition of the PEG76 molecule
was determined to be important in increasing the bioavailability of the peptide.17 Finally, a
fluorophore could be conjugated to the PEG76 polymer to produce the target molecule. The
fluorophores were chosen based on their similarities in absorbance and emission
characteristics to the fluorescent proteins currently genetically encoded in zebrafish
models.

3.1. Synthesis of peptide cFLFLFK

Figure 3. 2 Structure of target molecule, peptide FLFLFK, capped with a cinnamoyl group.

A procedure modified from Zhang, et al., was followed to synthesize the short
hexapeptide, FLFLFK (Figure 3.2). This peptide was synthesized via manual and
automated coupling procedures. Similar conditions were used to cap the peptide with a
cinnamoyl group.
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3.1.1 Selection of Resin Fmoc-PAL AM

Linker
Figure 3. 3 Structure Fmoc-PAL AM resin, consisting of an Fmoc-protected linker attached to a polystyrene
bead.

For the synthesis of the peptide cFLFLFK, an Fmoc-protected PAL AM resin was
selected (Figure 3.3). This solid support is composed of a polystyrene bead and a linker
that attached to and extends from the bead. The use of polystyrene as the anchor for peptide
synthesis allows for a more uniform reaction mixture because this material is porous when
swelled. When swelled, reagents and solvents are able to pass through the pores of the
material.
This resin was also selected based on its linker, as it would result in a carboxamide
at the C-terminus after cleavage from the solid support, rather than the typical carboxylate.
The carboxamide serves as a pseudo protecting group since the amide is less likely to be
deprotonated and form the conjugate base of the amide. The formation of the amide allows
for selective reactivity of the terminal primary amine on the Lysine residue in later
reactions when the polyethylene glycol polymer is attached through a conjugation reaction.
Another important aspect in selecting a resin is its loading value. For the FmocPAL AM resin, the loading value ranges between 0.50-0.80 mmol/g. This means that for
every gram of resin that participates in a synthesis, between 0.50 and 0.80 mmol of product
is expected to be produced. This value ranges because, while each polystyrene bead has
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multiple linkers attached, not every linker will load an amino acid. Furthermore, in
subsequent coupling reactions, amino acid residues may not be loaded onto every peptide
on the solid support. The combination of the three aspects discussed above contributed to
the final selection of the Fmoc-PAL AM resin for this synthesis.

3.1.2 Protecting Groups

Figure 3. 4 Structures of the (a) fluorenylmethyloxycarbonyl (Fmoc) protecting group and (b) the tertbutyloxycarbonyl (Boc) protecting group

A key aspect in solid phase synthesis is the use of protecting groups. In this study,
the two that are utilized are the fluorenylmethyloxycarbonyl (Fmoc) protecting group (Fig.
3.4a) and the tert-butyloxycarbonyl (Boc) protecting group (Fig 3.4b), which are
considered to be orthogonal to one another. The Fmoc group is stable in acid conditions
but becomes labile under basic conditions, while the Boc group is stable in basic conditions
and labile in acidic conditions. The inverse relationship of the stabilities and reactivities of
these two groups allows for control of specific functional groups throughout a reaction.
In this study, the Fmoc group was used to control the reactivity of the primary amine
at the terminal end of the linker of the resin, as well as the amines of the amino acid residues
that participate in the peptide backbone. For removal of the Fmoc group, a 20% 4methylpiperidine solution was used.
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The primary amine at the terminal end of the lysine residue side chain was of
concern due to its reactivity and the possibility of forming impurities through side chain
involved reactions. It could not be protected with an Fmoc group, as it was the first amino
acid residue to be loaded onto the solid support, and the reactivity would be recovered in
the next deprotection step. Thus, a lysine compound was selected that had an Fmoc group
protecting the terminal amine that would participate in the peptide backbone and a Boc
group protecting the terminal amine in the side chain of the lysine residue. Because of the
orthogonal properties of the two protecting groups, the amine of the lysine side chain would
remain unfunctionalized throughout synthesis of the peptide. After completion of the
synthesis the functionality of the amine in the lysine side chain could be recovered by
removing the Boc protecting group in a trifluoracetic acid cocktail.
The selection of the PAL-AM resin was also related to this idea of orthogonal
protecting group schemes. The linker attached to the polystyrene bead is stable in basic
conditions and becomes labile only in acidic conditions, which makes it a good support
choice for Fmoc-chemistry synthetic routes. This provides a selective route for cleavage of
the peptide from the resin after the completion of the synthesis.

3.1.3. Fmoc deprotection conditions
Because the Fmoc protecting group was used to reduce nucleophilicity of the amine
groups in the amino acid residues, a solution of 4-methylpiperidine was used for removal
of this protecting group. The 20% 4-methyl piperidine solution was prepared in dry
dimethylformamide (DMF). The dry DMF used was purchased, but it was also stored with
molecular sieves to maintain dryness. This polar, aprotic solvent was chosen in order to
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reduce the likelihood of hydrolysis of the peptide backbone occurring throughout the
synthesis of the peptide. A lower water content in the solvent was desired for this purpose
as well.
A challenge with the 4-methylpiperidine solution was the rate at which the 4methylpiperidine compound underwent oxidation. For this reason, small quantities of
solution were prepared at a time. For manual coupling procedures, the solution was
prepared several times through the course of the synthesis. For automatic synthesis, the
solution was able to be prepared for one synthesis and the remaining solution was discarded
before the next synthesis.

Figure 3. 5 Mechanism of removal of the Fmoc protecting group by 4-methylpiperidne to recover
functionality of terminal amine of the peptide on solid support.

In the deprotection reaction the 4-methylpiperidine deprotonates the alpha proton,
transforming the aromatic system in the Fmoc molecule to become a good leaving group
(Figure 3.5). The reaction proceeds an E2 type elimination reaction, producing a byproduct
molecule. Decarboxylation proceeds and produces CO2 gas as another byproduct. The
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aromatic byproduct remains in the 20% 4-methylpiperidine solution and is removed when
the deprotection solution is removed.
In order to maintain a uniform reaction solution, the reaction vessel was incubated
and agitated with each deprotection. Reaction times never exceeded more than one hour,
as the possibility of the resin being degraded by the 4-methylpiperidine compound
increased over time. The resin and reaction column were thoroughly washed after each
deprotection treatment, in order to fully remove all 4-methylpiperidine. Even trace amounts
of the deprotection solution could result in removal of the Fmoc group protecting
subsequent amino acid resides. This could result in double coupling events and would
ultimately change the peptide sequence. Consequentially, with the thorough washings, the
Fmoc byproduct was removed after each deprotection.

3.1.4. Reaction monitoring via UV-vis spectroscopy

Trial 1: UV-vis measurements after
coupling
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Figure 3. 6 UV-vis measurements at 290 nm of Fmoc washings after coupling cycles.
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During synthesis via manual coupling, the loading of each amino acid fragment was
monitored via UV-vis spectroscopy. The deprotection solution, containing the aromatic
Fmoc byproduct formed in the deprotection scheme (Figure 3.6) was analyzed after each
coupling reaction, as well as the deprotection to remove the Fmoc group from the resin.
After several washing cycles, DMF washings were analyzed to determine that no Fmoc
byproducts remained and confirm that the resin and reaction volume could be cleaned
efficiently with DMF rinses.
A full absorption spectrum was measured for analysis. It was expected for the
highest absorbance to occur at 290 nm. It was also predicted that this method of monitoring
reaction progress would provide insight into the percent of each coupling. As previously
discussed, the loading percentage decreases after each coupling cycle. As a result, it was
expected for intensity of absorbance to decrease at 290 nm after each coupling cycle. This
trend, however, was not observed.
The challenge with this method of monitoring the reaction was removing a
consistent amount of resin for analysis after each coupling of the next amino acid. Due to
the small amount of resin collected each time (about 1-2 mg), it was difficult to weigh the
amount analyzed accurately and the loading percent could not be concluded from this
method.
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Figure 3. 7 Standardized curve measuring presence of Fmoc byproduct.

In later trials, rather than drying the resin and attempting to record a weight, 20 µL
aliquot of solution containing resin was removed and then dried and weighed. Then this
sample was treated with the deprotection solution, which was collected for analysis. The
challenge with this method was ensuring that the resin was evenly suspended in the solution
when the sample was taken, and a consistent amount of resin still was unable to be collected
for analysis. The absorbance values were standardized to correct for the varying amounts
of resin that were analyzed (Figure 3.7). From the UV-vis measurements, it could be
determined that the Fmoc deprotection was occurring at each step, however, the percent of
coupling after each cycle could not be determined throughout the synthesis.
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3.1.5. Coupling conditions -

= R1

Figure 3. 8 Coupling mechanism using HCTU as coupling reagent. Hunig’s base (N,Ndiisopropylethylamine) was used as the base.
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For the loading of subsequent amino acid residues, there were three major
components in the coupling cocktail, which were the coupling reagent, a base, and the
amino acid residues. The coupling reagent chosen for this synthesis was HCTU (O-(1H-6Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate).

This

compound was developed to have two functionalities in coupling reactions (Figure 3.8).
First, a base is used to form the carboxylate of the amino acid residue. Hunig’s base
(diisopropylethylamine) in excess was utilized in this synthesis for this purpose. Then the
carboxylate performs a nucleophilic attack on the carbon of the amide bond. An ester
intermediate forms containing the amino acid residue and the HCTU compound is
transformed so that it contains a deprotonated hydroxyl. The coupling reagent now serves
as the nucleophile and the carbon within the carbonyl of the ester intermediate acts at the
electrophile. The amino acid is transferred back to the coupling reagent to form the fully
activated amino acid residue, and tetramethyl urea is produced as a byproduct. The terminal
amine of the peptide on solid support is able to attack the activated amino acid residue at
the electrophile carbon of the carbonyl. A tetrahedral intermediate is formed, and the
product that forms results in the new amino acid residue finally being attached to the
peptide chain on the solid support. The coupling reagent fragment is produced as
byproduct. The excess base is used to deprotonate the nitrogen in the newly formed amide
bond, and the elongation of the peptide is complete.
As previously discussed, in manual coupling procedures, the amino acid residue
was activated in a coupling cocktail prepared externally from the reaction vessel containing
the resin. For automated synthesis, the coupling cocktail was prepared within the reaction
vessel already containing resin. In both procedures, the amino acid residues to be coupled
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were selectively activated. During manual coupling procedures, the coupling cocktail was
prepared immediately before the reaction was to begin, as it was learned that the activated
amino acid has limited stability before degrading. But, because the amino acid compound
and the coupling reagent needed to be dissolved in solvent, the solution was prepared
externally before being transferred to the reaction vessel.

3.1.6. Cleavage and Boc deprotection conditions R1 =

= R2

Figure 3. 9 (a) Mechanism for cleavage of peptide and (b) global deprotection of Boc protecting group
attached to the lysine residue sidechain.

After the completion of the synthesis and capping of the peptide, it was removed
from the solid support. A cleavage cocktail of trifluoroacetic acid (TFA), water, and
triisopropylsilane (TIPS) was used (Figure 3.9). This cleavage cocktail also resulted in the
global deprotection of the Boc side chain on the lysine residue. The water and TIPS
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compound were used as nucleophilic scavengers for the carbocation produced in each
reaction. Carbon dioxide gas was also produced as a byproduct in each of these reactions.
The reaction solution and byproducts were removed by evaporation.

3.1.7. Isolation and purification techniques of cFLFLFK 3.1.7.1. Purification of cFLFLFK via high performance liquid chromatography (HPLC)
For purification, the crude product was dissolved in methanol for HPLC analysis
and purification. In several trials, the product was attempted to be dissolved in water,
however, a gel-like substance formed. Methanol was added, and the gel partially dissolved
and solid precipitates formed. Centrifugation and syringe filtration were used to remove
the solid particles, and the methanol solution was injected on the analytical HPLC. It was
hypothesized that the formation of the gel was an effect of residual TFA and base forming
a salt.
3.1.7.2. Isolation via cold ether precipitation
In one trial, after the completion of peptide synthesis, isolation of product was
attempted using cold diethylether. It was expected for the product to crash out of solution.
This precipitation event did not occur immediately, and the solution was left overnight at
4°C, however no precipitates formed. It was later determined that this isolation method
was not possible due to the nonpolar characteristics of the molecule. The modifications to
yield C-terminus amide and the N-terminus capped with the cinnamoyl group, the product
was highly nonpolar. The compound would not form a precipitate in the cold ether solution.
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3.1.9. Characterization of peptide cFLFLFK

cFLFLFK

Figure 3. 10 Chromatogram of LC/MS analysis of peptide cFLFLFK

After purification, the product was characterized via liquid chromatography/mass
spectrometry. The product was expected to be protonated at the terminal amine of the lysine
residue sidechain, and had an expected mass of 944.5 g/mol. Mass spectrometry results
measured a mass of 943.7 g/mol. The slight difference (0.9 g/mol) was attributed to error
of the instrument, and it was concluded that the product was most likely the expected
peptide.
The product was further analyzed via 1H NMR and 13C NMR (Figure 3.11). In both
spectra, various regions showed chemical shifts expected for the different characteristics
present in the target molecule. Based on these spectra, it was further concluded that the
desired product had been synthesized.
Neither of these techniques provide insight to the order of the connectivity of the
amino acid fragments in the peptide chain. However, based on the reaction conditions and
the low likelihood of contamination occurring among amino acid compounds, and the
thorough washings that occurred in between each reaction step, it was concluded that the
peptide had been produced with the desired sequence.
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(a)

(b)

Figure 3. 11 (a) 1H NMR spectrum of peptide cFLFLFK (solvent: methanol-D) and (b) 13C NMR spectrum
of peptide cFLFLFK (solvent: methanol-D)
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3.1.10. Summary of synthesis of peptide cFLFLFK
Several trials were performed to attempt to optimize reaction conditions and
isolation and purification methods. In the case of manual coupling, the largest hurdle to
overcome was isolating and purifying product. It was determined that purification via
HPLC was the most efficient tool for this purpose. Smaller challenges that presented
involved the stability window of activated amino acid fragments and the ability to monitor
the progress of the reaction after each coupling cycle.
In the case of automated peptide synthesis, the largest issue had to do with the
system software and creating reaction files to run the synthesis. Smaller technicalities
related to the instrument also needed to be addressed before the instrument was run
properly. Optimization of reagent concentrations was another obstacle that was
troubleshooted for these reactions. Once these issues were resolved, the automated
synthesis protocol proved to be the superior route for synthesizing this product. The time
taken to produce the peptide was reduced from two weeks to about ten hours. One downside
to this method of synthesis is the inability to monitor the reaction with each coupling cycle.
Another downside in this synthetic route is the need to perform the final coupling with the
cinnamoyl cap manually. However, these disadvantages are mitigated by the efficiency of
this instrument, and the sizeable reduction of time needed to produce product.

3.2. Conjugation of polyethylene glycol (PEG) polymer
Relative to most biomacromolecules, the peptide cFLFLFK is very hydrophobic.
This causes the bioavailability of the molecule to decrease in living systems. The low
bioavailability is usually due to the compound low solubility or segregation to fatty tissues,
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rather than the intended target cells, which usually reside in relatively aqueous
environments. To increase bioavailability, a polyethylene glycol molecule was conjugated
to the terminal amine of the lysine residue in the peptide chain.

3.2.1 Selection of biheterofunctionalized PEG76 moiety, tBOC-PEG76-NHS ester -

Figure 3. 12 Structure of biheterofunctionalized tBoc-PEG76-NHS ester

A PEG polymer with an average length of 76 repeat units was selected that was
biheterofuntionalized in order for the conjugate addition to occur selectively at the terminal
amine of the lysine residue size chain (Figure 3.12). One end of the polymer was
functionalized with an N-hydroxysuccinimide ester. The other end of the polymer was
functionalized with a primary amine. The reactivity of this terminal amine was masked
with use of a Boc protecting group. The reactivity could be later recovered after removal
of the Boc group using a TFA cleavage cocktail. The cleavage of the Boc group proceeded
as the mechanism described in section 3.1.6 and shown in Figure 3.9.
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3.2.2. Reaction conditions for conjugation of tBoc-PEG76-NHS ester to cFLFLFK

Figure 3. 13 Reaction mechanism for the conjugate addition of the tBoc-PEG76-NHS ester to the terminal
amine of the lysine residue side chain.

The conjugate addition was completed in an acetonitrile sodium borate buffer
solution of pH 8.5 over a period of 24 hours (Figure 3.13). The reaction progress was
monitored via analytical HPLC (Figure A1). The PEG76 molecule is does not absorb light,
which posed as a challenged in this experiment. The absorbance was measured at 254 nm
to monitor the peptide compound. To selectively monitor the PEG76 molecule, absorbance
was measured at 215 nm. At this wavelength, the Boc protecting group could be traced on
the PEG76 molecule, and as the polymer was the only molecule with this protecting group,
absorbance at this wavelength would be indicative of PEG76 only.
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The reaction was run in basic conditions, to control the deprotonation of the
terminal amine of the lysine residue side chain (Figure 3.10). This transformed this amine
into a good nucleophile, which attacked at the electrophilic carbon of the Nhydroxysuccinimide ester. A tetrahedral intermediate formed and when it degraded, the Nhydroxysuccinimide acted as the leaving group produced the conjugated product.

3.2.3. Purification of cFLFLFK-PEG76-Boc via HPLC
The product cFLFLFK-PEG76-Boc was purified via HPLC. After the conjugate
addition of the PEG polymer, the product was able to be dissolved water. Purification was
performed using the same methods optimized in the analytical experiments. In two trials,
the peak collected for characterization did not have the expected retention time. In one trial,
the peak eluted at 13.5 minutes. In another, the peak eluted at 2.5 minutes. The varying
retention times was attributed to the loading difference between the analytical column and
the preparatory columns. In both trials, the UV-vis data were a strong indicator for selecting
which peaks to collect and perform characterization analyses on.
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3.2.4. Characterization via mass spectrometry (MALDI-TOF)

cFLFLFK-PEG76-Boc

Boc-PEG76-NHS

Figure 3. 14 Mass spectrometry spectrum of cFLFLFK-PEG76-Boc compound (method: MALDI-TOF)

As previously discussed, a PEG76 moeity was selected, which has an average
molecular weight of 3.4 kDa. The length of this polymer was determined in previous
studies to increase the bioavailability of the peptide when attached. After conjugation, the
calculated mass of the product was 4489.6 g/mol. Due to the mass of this product, mass
spectrometry was performed using a matrix assisted laser desorption ionization-time of
flight (MALDI-TOF) method (Figure 3.14).
The resulting spectrum for this analysis appeared as a bimodal distribution curve.
The distribution nature of the curve was attributed to the factor of the PEG polymer that
was purchased exists in a range of lengths, with an average of 76 repeat units. The average
molecular weight of the compound (3.4 kDa) reflects this characteristic of the polymer.
This was also confirmed by calculating the mass difference between two neighboring peaks
on the curves. The PEG monomer has a molecular weight of 44.053 g/mol, and the mass
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difference between neighboring peaks was calculated to be 44.05 g/mol, confirming that
the distribution curve was a result of the varying lengths of PEG polymer.
It was also confirmed that the bimodal distribution was a result of unconjugated
PEG76 compounding remaining in solution with the product. The first distribution curve
correlated to masses expected for the tBoc-PEG76-NHS ester compound. The second
correlated to masses expected for the product. The mass resulting from the analysis was
4511.9 g/mol, and it was found that the extra unexpected mass was caused by the addition
of a sodium ion (MW = 23.0 g/mol). These ions could have been contributed from matrix
or from the glassware the peptide was stored in. When the mass of the product was
recalculated to consider the addition of a sodium ion, the expected mass was 4512.6 g/mol.
The 0.7 g/mol difference was attributed to instrument error, and based on this analysis, it
was concluded that the conjugate addition of the PEG76 polymer was successful.

H2N-PEG76-NHS
H2N-PEG76-cFLFLFK

Figure 3. 15 Mass spectrometry spectrum of cFLFLFK-PEG76-NH2 compound (method: MALDI-TOF)
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In a second study, cleavage of the Boc protecting group was performed before
analyzing product (Figure 3.15). A similar spectrum resulted, showing two distribution
curves. The distribution resulting from the varying length of peptide, and the two curves
resulting from the presence of unconjugated PEG76 compound as well as the product was
confirmed following similar calculations. After removal of the Boc group, the expected
mass of the compound was 4412.5 g/mol (considering the addition of a Na+ ion). The
observed mass was 4410.9 g/mol, resulting in a 1.7 g/mol difference in this study. This
difference was again attributed to instrument error, and it was concluded that product had
formed and the Boc deprotection was successful.

3.3. Conjugation of fluorophore 5(6)-ROX NHS ester
The final component of the overall target molecule involves the attachment of a
fluorophore. The fluorophore chosen was analogous to one of the proteins that are
expressed in the transgenic zebrafish model. The fluorophore, 5(6)-ROX is of the
rhodamine family, and has been modified to absorb at 580 nm and emit at 601 nm. It was
functionalized with an NHS ester, and coupling to the terminal amine of the PEG76
molecule proceeded similarly to the conjugate addition of the PEG76 polymer to the
terminal amine of the lysine residue sidechain.

3.3.1. Conjugation conditions
A procedure published by the manufacturers of the fluorophore was adapted for
this reaction.24 Due to the narrow window of solvents that the fluorophore is soluble in,
dimethyl sulfoxide (DMSO) was chosen for this reaction, as it is a polar aprotic solvent.
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Because the selected fluorophore was functionalized with an NHS ester, a buffer with a pH
of 8.5 was selected. NHS esters are strongly reactive with primary amines in environments
of pH 7.0-9.0. The mechanism of this reaction was similar to that of the reaction mechanism
detailed in section 3.2.2. and shown in Figure 3.13. The reaction was monitored via HPLC
to determine whether the starting material was being consumed (Figure A2). After
optimization of the mobile phase so that the fluorophore had a reasonable retention time
on the stationary phase, the retention time for both the fluorophore and the cFLFLFKPEG76-NH2 compound coincided at around 6 minutes. This however, was not problematic
due to the different wavelengths the two compounds were detected at by the UV-vis
detector. The peptide-PEG76 compound was detected at 215 nm and the fluorophore was
detected at 575 nm. The selectivity of these two wavelengths was determined by analyzing
two standard solutions of each compound separately. Through this study, the conjugation
reaction could be visualized and was confirmed by retention times that were detected at
both wavelengths.

3.3.2. Purification of cFLFLFK-PEG76-5(6)-ROX-NHS ester
Purification of this product was performed via size exclusion chromatography. The
calculated mass for this product was 4928.96 g/mol. Due to the size of the compound, a
Sephadex G-25 media was selected for the column. Before loading the compound on the
column, the sample was first condensed via rotary evaporation. However, the low solubility
of the fluorophore proved to be a challenge and a solid precipitate fell out of the small
amount of solution. The sample was re-dissolved in 0.8 mL of water to total about 1 mL of
sample. For loading, the sample was divided in half, and only 0.5 mL of sample was loaded
on the column at once.
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The sample was a vibrant purple color, a result from the 5(6)-ROX fluorophore.
This allowed for visualization of the bands that formed as the sample moved through the
Sephadex gel. Three apparent bands formed on the column. The first was very thin and a
pale purple color. The second was thicker in height, about 4 mm, and a dark magenta color.
The third band was much thicker, about 10 mm, and was a less vibrant magenta color. As
the bands separated and become more defined, the loss of uniformity of the bands was
observed. They became more wavy-looking than straight, as they neared the bottom of the
column, it was apparent that different sections of the bands were eluting at a varying rates.
It was hypothesized that this lack of uniformity in the appearance of the bands may have
been caused because such a small sample was loaded making it difficult to load it evenly
over the entire surface of the gel.
Based on the principles of size exclusion chromatography, however, it was still
expected for the largest molecules to elute from the column first, while the smaller particles
would retain on the column longer respective to their size. A total of 19 fractions were
collected in 1-mL aliquots and reserved for analysis to confirm the order of elution.
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3.3.3. Characterization via UV-vis spectroscopy -

Absorbance

Absorbance measurements
at 290 nm and 580 nm
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Figure 3. 16 UV-vis analysis of fractions from purification of cFLFLFK-PEG76-5(6)-ROX compound via
size exclusion chromatography. Figure (a) shows the full spectrum absorbance scan per fraction and Figure
(b) shows comparison of fractions that absorbed at 290 nm and fractions that absorbed at 580 nm.

The 19 fractions were all analyzed using UV-vis spectroscopy. First, specific
wavelength scans taken of the samples. Absorbance was measured at 254 nm to determine
whether the peptide containing compound was present. This wavelength was chosen for
the UV-vis active aromatic side chain in the phenylalanine residues. To detect the presence
of the fluorophore, absorbance was measured at 580 nm. Results of these scans were
inconclusive and did not reflect the presence of either compound.
Full spectrum absorbance scans measured from 230 nm to 1000 nm were then taken
of all samples. The results of these scans showed high absorbance at 290 nm and 580 nm
in fractions 11-17 (Figure 3.16). It was determined that the absorbance at 580 was
comparable to the absorbance first predicted for the fluorophore (575 nm) and was most
likely reflective of the presence of fluorophore. It was hypothesized that the higher
absorbance at 290 nm was an effect of the material the samples were scanned in. The multi54

well plate was composed of polystyrene, which absorbs in the range of 230 nm to 280 nm.
This hypothesis was supported by the data from the UV-vis scans, which had consistently
recorded a zero value for all fractions in the 230 nm to 280 nm range.
Despite the lack of absorbance between 230 nm and 280 nm, these UV-vis analyses
still provided information on the composition of the fractions. The wavelengths 290 nm
and 580 nm were selected for the comparison of the nineteen fractions, which is illustrated
in Figure 3.13b. Fractions 1-10 showed absorbance at 290 nm. The intensity was low, but
was expected as a very low amount of starting material was used in this conjugation
reaction. Furthermore, only half of the sample was loaded on the column for purification.
Fractions 11-17 showed absorbance at both wavelengths, which suggested the presence of
both peptide-PEG76 compound and the fluorophore. Based on this comparison, fractions 410 and then fractions 11-17 were condensed for further analysis.

UV-vis analysis of fraction samples
3

Absorbance
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0.5
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800
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860
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Fractions 11-17

Figure 3. 17 UV-vis analysis of (a) sample containing fractions 4-10 and (b) sample containing fractions 1117.
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To avoid the absorbance issues at wavelength 254 nm caused by the material of the
plate used in the first UV-vis study, the two samples containing fractions 4-10 and 11-17
were measured in a quartz cuvette. The sample containing fractions 4-10 showed no
absorbance at neither 254 nm nor 580 nm (Figure 3.a) However, the sample containing
fractions 11-17 showed absorbance at both the target wavelengths. This was suggestive of
the presence of both compound as well as the fluorophore. The disadvantage to this analysis
however, is its limitation in providing detail in regard to connectivity of the two molecule.
The presence of absorbance at both wavelengths cannot confirm that the conjugation
reaction was successful. As a result, this sample will need further analysis to determine
whether the two molecules underwent reaction and product was produced.
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CHAPTER 4: CONCLUSION AND FUTURE WORK

The goal of this project was to synthesize a bioactive fluorescently active probe that
would serve as a synthetic replacement for the use of a transgenic zebrafish model in hostpathogen interaction fluorescence studies. In this study, the production of the bioactive
peptide, cFLFLFK, and production of the peptide-PEG76 compound was completed
successfully. The peptide was synthesized using manual and automated coupling
procedures. The PEG76 polymer was attached to the terminal amine of the lysine residue
side chain via a conjugative addition in a buffer system. The synthesis of these two
molecules was confirmed through 1H NMR and 13C NMR and mass spectrometry analyses.
A third molecule, the peptide-PEG76-fluorophore compound was synthesized using
a 5(6)-ROX fluorophore through a conjugative addition in a buffer system. This third
molecule was purified via size exclusion chromatography, and characterization
experiments were performed with UV-vis analysis. However, further characterizations
tests must be conducted to confirm product, such as mass spectrometry. If product is not
confirmed, another goal will be to explore other reaction conditions for this final
conjugation.
Once final product is confirmed, future work should include the validation of the
product in a zebrafish model. Upon validation, if the proposed synthetic route in this project
is approved, other small molecule fluorophores may begin to be considered to serve as
modifications to the probe.
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Appendix A

HPLC experiments to monitor coupling of peptide and tBoc-PEG76 compound

e
d
c
b
a
Figure A 1 HPLC analysis of conjugate addition reaction of tBoc-PEG76-NHS ester.
(stationary phase: C18; mobile phase: water:acetonitrile, 50-80%, 10 minutes, UV-vis
detection at 215 nm [red] and 254 nm [purple])
Table A. 1 HPLC experiments monitoring PEG76 conjugation
Time (hr)
Trace
0
a
1
b
3
c
4
d
24
e

61

Appendix B

HPLC experiments monitoring coupling of cFLFLFK-PEG76 and 5(6)-ROX NHS ester

h
g
f
e
d
c
b
a

Figure A 2 HPLC analysis of conjugate addition reaction of the fluorophore 5(6)-ROXNHS ester
Table A. 2 HPLC experiments monitoring fluorophore conjugation
Time
Sample
254 nm
5(6)-ROX NHS ester in a
Purple
water
cFLFLFK-PEG-NH2 in b
Dark blue
water
0
c
Blue
0.5
d
Blue
1
e
Blue
3
f
Blue
4
g
Blue
20
h
Blue
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575 nm
Blue
Light blue
Pink
Pink
Pink
Pink
Pink
Pink

Appendix C

ChemFile for synthesis of peptide FLFLFK via automated coupling procedures
16:52:01.56
16:52:01.94
16:52:02.27
16:52:03.75
16:52:05.07
16:52:05.40
16:52:08.75
17:52:12.03
17:52:12.36
17:54:10.45
17:54:41.48
17:54:51.42
17:54:53.18
17:59:55.32
17:59:55.71
18:00:53.44
18:00:53.60
18:01:03.49
18:01:05.30
18:21:07.18
18:21:07.56
18:22:05.46
18:22:05.62
18:22:15.51
18:22:15.89
18:22:17.21
18:22:17.54
SynthPos=17
18:22:17.59
…
18:22:17.59
18:22:19.52
18:22:28.69
18:22:38.69
18:22:47.91
18:23:07.25
18:23:07.96
18:23:08.35
18:23:08.35
18:23:11.20

Starting ChemFile - C:\AAPPTEC\SNI144.CHM
1 REM ** This is the data for cycle 1. ** SynthPos=1
2 <Set Active> SynthPos=2
3 Goto ChemFile swell2.cht, line 1 SynthPos=3
1 REM SWELL THE RESIN SynthPos=4
2 Mix "RV48" for 60.00 minutes at 600 rpm(s) and wait. SynthPos=5
Mixer 0 on at 600 rpm
Mixer 0 off
3 Empty RV48 for 2.000 minute(s) SynthPos=6
4 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=7
Washing with DMF (A) 3.00ml per vessel to RV48
5 Mix "RV48" for 5.00 minutes at 450 rpm(s) and wait. SynthPos=8
Mixer 0 on at 450 rpm
Mixer 0 off
6 Empty RV48 for 1.000 minute(s) SynthPos=9
7 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=10
Washing with DMF (A) 3.00ml per vessel to RV48
8 Mix "RV48" for 20.00 minutes at 450 rpm(s) and wait. SynthPos=11
Mixer 0 on at 450 rpm
Mixer 0 off
9 Empty RV48 for 1.000 minute(s) SynthPos=12
10 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=13
Washing with DMF (A) 3.00ml per vessel to RV48
11 Return SynthPos=14
4 Goto ChemFile depro48.cht, line 1 SynthPos=15
1 REM FMOC DEPROTECTION SynthPos=16
2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
Pick up 9000 microL and 0 steps
A2700R
Pick up 9000 microL and 0 steps
A2700R
Pick up 110 microL and 0 steps
A33R
Dispense 99 microL and 0 steps
A30R
--Cleaned Probe with 18000µl of DMF (1)
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18:23:11.97
18:23:12.41
18:23:12.74
18:23:12.74
18:23:18.73
18:23:25.43
18:23:29.22
18:23:29.22
18:23:35.53
18:23:37.73
18:23:37.73
18:23:44.93
18:23:45.31
18:23:45.31
18:23:49.65
18:23:52.94
18:23:54.70
18:26:55.68
18:26:56.07
18:28:24.44
SynthPos=20
18:28:24.44
…
18:28:24.44
18:28:25.16
18:28:25.92
18:28:26.25
18:28:26.25
18:28:32.24
18:28:38.94
18:28:42.73
18:28:42.73
18:28:48.83
18:28:51.08
18:28:51.08
18:28:58.22
18:28:58.66
18:28:58.66
18:29:02.94
18:29:06.24
18:29:08.05
18:37:10.74
18:37:11.07
18:38:39.44
18:38:39.77
18:38:41.09

Pick up 110 microL and 0 steps
A33R
Dispense 99 microL and 0 steps
A30R
Pick up 2225 microL and 0 steps
A668R
Dispense 2126 microL and 0 steps
A638R
--Aspirated 2001µl from Pip-350mL[1](PIP)
Dispense 126 microL and 0 steps
A38R
--Dispensed 2000µl to RV48[11]
Dispense 1 microL and 0 steps
A0R
--Dispensed 126µl to RV48[11]
3 Mix "RV48" for 3.00 minutes at 450 rpm(s) and wait. SynthPos=18
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=19
5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
Pick up 110 microL and 0 steps
A33R
Dispense 99 microL and 0 steps
A30R
Pick up 2225 microL and 0 steps
A668R
Dispense 2126 microL and 0 steps
A638R
--Aspirated 2001µl from Pip-350mL[1](PIP)
Dispense 126 microL and 0 steps
A38R
--Dispensed 2000µl to RV48[11]
Dispense 1 microL and 0 steps
A0R
--Dispensed 126µl to RV48[11]
6 Mix "RV48" for 8.00 minutes at 450 rpm(s) and wait. SynthPos=21
Mixer 0 on at 450 rpm
Mixer 0 off
7 Empty RV48 for 1.500 minute(s) SynthPos=22
8 Return SynthPos=23
5 Goto ChemFile washdp48.cht, line 1 SynthPos=24
1 REM Wash after Deprotection SynthPos=25
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18:38:41.47 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=26
18:39:12.51 Washing with DMF (B) 3.00ml per vessel to RV48
18:39:22.45 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=27
18:39:24.21 Mixer 0 on at 450 rpm
18:40:26.16 Mixer 0 off
18:40:26.49 4 Empty RV48 for 1.500 minute(s) SynthPos=28
18:41:54.48 5 Repeat from step 2, 3 times SynthPos=29
18:41:55.80 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=30
18:41:55.97 Washing with DMF (B) 3.00ml per vessel to RV48
18:42:05.91 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=31
18:42:07.66 Mixer 0 on at 450 rpm
18:43:09.24 Mixer 0 off
18:43:09.57 4 Empty RV48 for 1.500 minute(s) SynthPos=32
18:44:37.45 5 Repeat from step 2, 3 times SynthPos=33
18:44:38.76 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=34
18:44:38.93 Washing with DMF (B) 3.00ml per vessel to RV48
18:44:48.87 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=35
18:44:50.63 Mixer 0 on at 450 rpm
18:45:53.24 Mixer 0 off
18:45:53.57 4 Empty RV48 for 1.500 minute(s) SynthPos=36
18:47:21.45 5 Repeat from step 2, 3 times SynthPos=37
18:47:22.77 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=38
18:47:22.94 Washing with DMF (B) 3.00ml per vessel to RV48
18:47:32.82 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=39
18:47:34.64 Mixer 0 on at 450 rpm
18:48:36.70 Mixer 0 off
18:48:37.03 4 Empty RV48 for 1.500 minute(s) SynthPos=40
18:50:05.46 5 Repeat from step 2, 3 times SynthPos=41
18:50:06.78 6 Return SynthPos=42
18:50:07.16 6 REM HBTU48 SynthPos=43
18:50:07.49 7 Dispense Sequence SNI141.dsp with 0.699ml to RV48 rack using DMF
(1) SynthPos=44
18:50:07.49 Dispensing from Rack 4x7 vessel 11 to Rack RV48 vessel 11
18:50:09.42 Pick up 4000 microL and 0 steps
18:50:13.65 A1200R
18:50:27.93 Pick up 110 microL and 0 steps
18:50:28.69 A33R
18:50:29.02 Dispense 99 microL and 0 steps
18:50:29.02 A30R
18:50:31.94 --Cleaned Probe with 4000µl of DMF (1)
18:50:32.65 Pick up 110 microL and 0 steps
18:50:33.03 A33R
18:50:33.36 Dispense 99 microL and 0 steps
18:50:33.36 A30R
18:50:38.91 Pick up 924 microL and 0 steps
18:50:41.66 A277R
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18:50:45.34 Dispense 823 microL and 0 steps
18:50:45.34 A247R
18:50:51.43 --Aspirated 698µl from 4x7[11](Lys(Boc))
18:50:53.47 Dispense 0 microL and 0 steps
18:50:53.47 A0R
18:50:58.85 --Dispensed 823µl to RV48[11]
18:51:02.09 8 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using
DMF (1) SynthPos=45
18:51:02.09 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
18:51:02.09 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
18:51:04.01 Pick up 2250 microL and 0 steps
18:51:06.43 A675R
18:51:19.01 Pick up 110 microL and 0 steps
18:51:19.78 A33R
18:51:20.11 Dispense 99 microL and 0 steps
18:51:20.11 A30R
18:51:23.02 --Cleaned Probe with 2250µl of DMF (1)
18:51:23.73 Pick up 110 microL and 0 steps
18:51:24.11 A33R
18:51:24.44 Dispense 99 microL and 0 steps
18:51:24.44 A30R
18:51:30.93 Pick up 924 microL and 0 steps
18:51:33.67 A277R
18:51:37.52 Dispense 823 microL and 0 steps
18:51:37.52 A247R
18:51:43.83 --Aspirated 698µl from HBTU-350mL[1](HCTU)
18:51:46.03 Dispense 124 microL and 0 steps
18:51:46.03 A37R
18:51:51.25 --Dispensed 700µl to RV48[11]
18:51:51.69 Dispense 0 microL and 0 steps
18:51:51.69 A0R
18:51:56.03 --Dispensed 123µl to RV48[11]
18:51:59.32 9 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using
DMF (1) SynthPos=46
18:51:59.32 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
18:51:59.32 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
18:52:01.19 Pick up 2250 microL and 0 steps
18:52:03.66 A675R
18:52:16.18 Pick up 110 microL and 0 steps
18:52:16.95 A33R
18:52:17.28 Dispense 99 microL and 0 steps
18:52:17.28 A30R
18:52:20.19 --Cleaned Probe with 2250µl of DMF (1)
18:52:20.85 Pick up 110 microL and 0 steps
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18:52:21.29
18:52:21.62
18:52:21.62
18:52:27.83
18:52:30.63
18:52:34.47
18:52:34.47
18:52:40.79
18:52:43.04
18:52:43.04
18:52:48.21
18:52:48.65
18:52:48.65
18:52:52.93
18:52:56.22
18:52:58.04
19:38:00.43
19:38:00.76
19:39:28.47
19:39:29.79
19:39:30.17
19:40:01.21
19:40:11.09
19:40:12.91
19:41:14.26
19:41:14.64
19:42:42.47
19:42:43.79
19:42:43.95
19:42:53.89
19:42:55.65
19:43:58.10
19:43:58.43
19:45:26.48
19:45:27.79
19:45:27.96
19:45:37.90
19:45:39.66
19:46:41.07
19:46:41.39
19:48:09.44
19:48:10.76
19:48:10.92
19:48:20.86
19:48:22.62
19:49:24.58

A33R
Dispense 99 microL and 0 steps
A30R
Pick up 924 microL and 0 steps
A277R
Dispense 823 microL and 0 steps
A247R
--Aspirated 698µl from DIEA-350mL[1](DIPEA)
Dispense 124 microL and 0 steps
A37R
--Dispensed 700µl to RV48[11]
Dispense 0 microL and 0 steps
A0R
--Dispensed 123µl to RV48[11]
10 Mix "RV48" for 45.00 minutes at 450 rpm(s) and wait. SynthPos=47
Mixer 0 on at 450 rpm
Mixer 0 off
11 Empty RV48 for 1.500 minute(s) SynthPos=48
12 Goto ChemFile washcp48.cht, line 1 SynthPos=49
1 REM Wash after Coupling SynthPos=50
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=51
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=52
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=53
5 Repeat from step 2, 3 times SynthPos=54
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=55
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=56
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=57
5 Repeat from step 2, 3 times SynthPos=58
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=59
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=60
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=61
5 Repeat from step 2, 3 times SynthPos=62
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=63
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=64
Mixer 0 on at 450 rpm
Mixer 0 off
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19:49:24.91
19:50:53.45
19:50:54.77
19:50:55.15
19:50:55.86
19:50:57.35
19:50:58.67
19:50:59.05
SynthPos=72
19:50:59.05
…
19:50:59.05
19:51:00.97
19:51:03.39
19:51:15.91
19:51:16.68
19:51:17.07
19:51:17.07
19:51:19.92
19:51:20.64
19:51:21.02
19:51:21.41
19:51:21.41
19:51:27.34
19:51:34.09
19:51:37.88
19:51:37.88
19:51:44.20
19:51:46.40
19:51:46.40
19:51:53.59
19:51:53.98
19:51:53.98
19:51:58.31
19:52:01.61
19:52:03.37
19:55:05.01
19:55:05.34
19:56:33.44
SynthPos=75
19:56:33.44
…
19:56:33.44
19:56:34.15
19:56:34.86
19:56:35.25

4 Empty RV48 for 1.500 minute(s) SynthPos=65
5 Repeat from step 2, 3 times SynthPos=66
6 Return SynthPos=67
13 REM ** This is the data for cycle 2. ** SynthPos=68
14 <Set Active> SynthPos=69
15 Goto ChemFile depro48.cht, line 1 SynthPos=70
1 REM FMOC DEPROTECTION SynthPos=71
2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
Pick up 2250 microL and 0 steps
A675R
Pick up 110 microL and 0 steps
A33R
Dispense 99 microL and 0 steps
A30R
--Cleaned Probe with 2250µl of DMF (1)
Pick up 110 microL and 0 steps
A33R
Dispense 99 microL and 0 steps
A30R
Pick up 2225 microL and 0 steps
A668R
Dispense 2126 microL and 0 steps
A638R
--Aspirated 2001µl from Pip-350mL[1](PIP)
Dispense 126 microL and 0 steps
A38R
--Dispensed 2000µl to RV48[11]
Dispense 1 microL and 0 steps
A0R
--Dispensed 126µl to RV48[11]
3 Mix "RV48" for 3.00 minutes at 450 rpm(s) and wait. SynthPos=73
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=74
5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
Pick up 110 microL and 0 steps
A33R
Dispense 99 microL and 0 steps
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19:56:35.25
19:56:41.24
19:56:47.94
19:56:51.78
19:56:51.78
19:56:57.88
19:57:00.13
19:57:00.13
19:57:07.27
19:57:07.66
19:57:07.66
19:57:11.99
19:57:15.29
19:57:17.05
20:05:19.62
20:05:19.95
20:06:48.44
20:06:48.77
20:06:50.14
20:06:50.47
20:07:21.50
20:07:31.44
20:07:33.20
20:08:35.32
20:08:35.65
20:10:03.48
20:10:04.80
20:10:04.96
20:10:14.90
20:10:16.66
20:11:18.73
20:11:19.11
20:12:47.49
20:12:48.80
20:12:48.97
20:12:58.91
20:13:00.67
20:14:02.07
20:14:02.46
20:15:30.45
20:15:31.77
20:15:31.93
20:15:41.87
20:15:43.63
20:16:46.08
20:16:46.47

A30R
Pick up 2225 microL and 0 steps
A668R
Dispense 2126 microL and 0 steps
A638R
--Aspirated 2001µl from Pip-350mL[1](PIP)
Dispense 126 microL and 0 steps
A38R
--Dispensed 2000µl to RV48[11]
Dispense 1 microL and 0 steps
A0R
--Dispensed 126µl to RV48[11]
6 Mix "RV48" for 8.00 minutes at 450 rpm(s) and wait. SynthPos=76
Mixer 0 on at 450 rpm
Mixer 0 off
7 Empty RV48 for 1.500 minute(s) SynthPos=77
8 Return SynthPos=78
16 Goto ChemFile washdp48.cht, line 1 SynthPos=79
1 REM Wash after Deprotection SynthPos=80
2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=81
Washing with DMF (B) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=82
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=83
5 Repeat from step 2, 3 times SynthPos=84
2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=85
Washing with DMF (B) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=86
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=87
5 Repeat from step 2, 3 times SynthPos=88
2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=89
Washing with DMF (B) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=90
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=91
5 Repeat from step 2, 3 times SynthPos=92
2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=93
Washing with DMF (B) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=94
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=95
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20:18:14.46 5 Repeat from step 2, 3 times SynthPos=96
20:18:15.78 6 Return SynthPos=97
20:18:16.16 17 REM HBTU48 SynthPos=98
20:18:16.49 18 Dispense Sequence SNI142.dsp with 0.699ml to RV48 rack using DMF
(1) SynthPos=99
20:18:16.49 Dispensing from Rack 4x7 vessel 13 to Rack RV48 vessel 11
20:18:18.36 Pick up 4000 microL and 0 steps
20:18:22.59 A1200R
20:18:36.92 Pick up 110 microL and 0 steps
20:18:37.64 A33R
20:18:38.02 Dispense 99 microL and 0 steps
20:18:38.02 A30R
20:18:40.88 --Cleaned Probe with 4000µl of DMF (1)
20:18:41.59 Pick up 110 microL and 0 steps
20:18:41.97 A33R
20:18:42.30 Dispense 99 microL and 0 steps
20:18:42.30 A30R
20:18:47.91 Pick up 924 microL and 0 steps
20:18:50.71 A277R
20:18:54.33 Dispense 823 microL and 0 steps
20:18:54.33 A247R
20:19:00.48 --Aspirated 698µl from 4x7[13](Phe)
20:19:02.35 Dispense 0 microL and 0 steps
20:19:02.35 A0R
20:19:07.73 --Dispensed 823µl to RV48[11]
20:19:11.03 19 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using
DMF (1) SynthPos=100
20:19:11.03 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
20:19:11.03 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
20:19:12.95 Pick up 2250 microL and 0 steps
20:19:15.37 A675R
20:19:27.95 Pick up 110 microL and 0 steps
20:19:28.66 A33R
20:19:29.05 Dispense 99 microL and 0 steps
20:19:29.05 A30R
20:19:31.90 --Cleaned Probe with 2250µl of DMF (1)
20:19:32.62 Pick up 110 microL and 0 steps
20:19:33.00 A33R
20:19:33.38 Dispense 99 microL and 0 steps
20:19:33.38 A30R
20:19:39.81 Pick up 924 microL and 0 steps
20:19:42.61 A277R
20:19:46.40 Dispense 823 microL and 0 steps
20:19:46.40 A247R
20:19:52.72 --Aspirated 698µl from HBTU-350mL[1](HCTU)
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20:19:54.97 Dispense 124 microL and 0 steps
20:19:54.97 A37R
20:20:00.19 --Dispensed 700µl to RV48[11]
20:20:00.57 Dispense 0 microL and 0 steps
20:20:00.57 A0R
20:20:04.91 --Dispensed 123µl to RV48[11]
20:20:08.21 20 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using
DMF (1) SynthPos=101
20:20:08.21 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
20:20:08.21 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
20:20:10.13 Pick up 2250 microL and 0 steps
20:20:12.55 A675R
20:20:25.12 Pick up 110 microL and 0 steps
20:20:25.89 A33R
20:20:26.22 Dispense 99 microL and 0 steps
20:20:26.22 A30R
20:20:29.24 --Cleaned Probe with 2250µl of DMF (1)
20:20:29.96 Pick up 110 microL and 0 steps
20:20:30.40 A33R
20:20:30.73 Dispense 99 microL and 0 steps
20:20:30.73 A30R
20:20:36.93 Pick up 924 microL and 0 steps
20:20:39.73 A277R
20:20:43.52 Dispense 823 microL and 0 steps
20:20:43.52 A247R
20:20:49.84 --Aspirated 698µl from DIEA-350mL[1](DIPEA)
20:20:52.09 Dispense 124 microL and 0 steps
20:20:52.09 A37R
20:20:57.31 --Dispensed 700µl to RV48[11]
20:20:57.70 Dispense 0 microL and 0 steps
20:20:57.70 A0R
20:21:02.03 --Dispensed 123µl to RV48[11]
20:21:05.28 21 Mix "RV48" for 45.00 minutes at 450 rpm(s) and wait. SynthPos=102
20:21:07.09 Mixer 0 on at 450 rpm
21:06:08.98 Mixer 0 off
21:06:09.31 22 Empty RV48 for 1.500 minute(s) SynthPos=103
21:07:37.47 23 Goto ChemFile washcp48.cht, line 1 SynthPos=104
21:07:38.79 1 REM Wash after Coupling SynthPos=105
21:07:39.17 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=106
21:08:10.20 Washing with DMF (A) 3.00ml per vessel to RV48
21:08:20.09 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=107
21:08:21.90 Mixer 0 on at 450 rpm
21:09:23.69 Mixer 0 off
21:09:24.02 4 Empty RV48 for 1.500 minute(s) SynthPos=108
21:10:52.45 5 Repeat from step 2, 3 times SynthPos=109
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21:10:53.77 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=110
21:10:53.94 Washing with DMF (A) 3.00ml per vessel to RV48
21:11:03.88 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=111
21:11:05.64 Mixer 0 on at 450 rpm
21:12:07.43 Mixer 0 off
21:12:07.76 4 Empty RV48 for 1.500 minute(s) SynthPos=112
21:13:35.47 5 Repeat from step 2, 3 times SynthPos=113
21:13:36.79 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=114
21:13:36.95 Washing with DMF (A) 3.00ml per vessel to RV48
21:13:46.90 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=115
21:13:48.65 Mixer 0 on at 450 rpm
21:14:51.27 Mixer 0 off
21:14:51.60 4 Empty RV48 for 1.500 minute(s) SynthPos=116
21:16:19.48 5 Repeat from step 2, 3 times SynthPos=117
21:16:20.80 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=118
21:16:20.96 Washing with DMF (A) 3.00ml per vessel to RV48
21:16:30.85 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=119
21:16:32.66 Mixer 0 on at 450 rpm
21:17:34.84 Mixer 0 off
21:17:35.22 4 Empty RV48 for 1.500 minute(s) SynthPos=120
21:19:03.49 5 Repeat from step 2, 3 times SynthPos=121
21:19:04.81 6 Return SynthPos=122
21:19:05.19 24 REM ** This is the data for cycle 3. ** SynthPos=123
21:19:05.52 25 <Set Active> SynthPos=124
21:19:07.00 26 Goto ChemFile depro48.cht, line 1 SynthPos=125
21:19:08.32 1 REM FMOC DEPROTECTION SynthPos=126
21:19:08.70 2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
SynthPos=127
21:19:08.70 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
21:19:08.70 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
21:19:10.57 Pick up 2250 microL and 0 steps
21:19:13.04 A675R
21:19:25.57 Pick up 110 microL and 0 steps
21:19:26.34 A33R
21:19:26.72 Dispense 99 microL and 0 steps
21:19:26.72 A30R
21:19:29.58 --Cleaned Probe with 2250µl of DMF (1)
21:19:30.29 Pick up 110 microL and 0 steps
21:19:30.68 A33R
21:19:31.06 Dispense 99 microL and 0 steps
21:19:31.06 A30R
21:19:36.99 Pick up 2225 microL and 0 steps
21:19:43.69 A668R
21:19:47.54 Dispense 2126 microL and 0 steps
21:19:47.54 A638R
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21:19:53.85 --Aspirated 2001µl from Pip-350mL[1](PIP)
21:19:56.05 Dispense 126 microL and 0 steps
21:19:56.05 A38R
21:20:03.19 --Dispensed 2000µl to RV48[11]
21:20:03.63 Dispense 1 microL and 0 steps
21:20:03.63 A0R
21:20:07.91 --Dispensed 126µl to RV48[11]
21:20:11.21 3 Mix "RV48" for 3.00 minutes at 450 rpm(s) and wait. SynthPos=128
21:20:13.02 Mixer 0 on at 450 rpm
21:23:14.88 Mixer 0 off
21:23:15.21 4 Empty RV48 for 1.500 minute(s) SynthPos=129
21:24:43.48 5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
SynthPos=130
21:24:43.48 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
21:24:43.48 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
21:24:44.19 Pick up 110 microL and 0 steps
21:24:44.96 A33R
21:24:45.29 Dispense 99 microL and 0 steps
21:24:45.29 A30R
21:24:51.28 Pick up 2225 microL and 0 steps
21:24:58.03 A668R
21:25:01.82 Dispense 2126 microL and 0 steps
21:25:01.82 A638R
21:25:07.92 --Aspirated 2001µl from Pip-350mL[1](PIP)
21:25:10.17 Dispense 126 microL and 0 steps
21:25:10.17 A38R
21:25:17.31 --Dispensed 2000µl to RV48[11]
21:25:17.69 Dispense 1 microL and 0 steps
21:25:17.69 A0R
21:25:22.03 --Dispensed 126µl to RV48[11]
21:25:25.33 6 Mix "RV48" for 8.00 minutes at 450 rpm(s) and wait. SynthPos=131
21:25:27.09 Mixer 0 on at 450 rpm
21:33:29.50 Mixer 0 off
21:33:29.83 7 Empty RV48 for 1.500 minute(s) SynthPos=132
21:34:57.49 8 Return SynthPos=133
21:34:57.82 27 Goto ChemFile washdp48.cht, line 1 SynthPos=134
21:34:59.19 1 REM Wash after Deprotection SynthPos=135
21:34:59.52 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=136
21:35:30.55 Washing with DMF (B) 3.00ml per vessel to RV48
21:35:40.44 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=137
21:35:42.25 Mixer 0 on at 450 rpm
21:36:43.93 Mixer 0 off
21:36:44.26 4 Empty RV48 for 1.500 minute(s) SynthPos=138
21:38:12.47 5 Repeat from step 2, 3 times SynthPos=139
21:38:13.79 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=140
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21:38:13.96 Washing with DMF (B) 3.00ml per vessel to RV48
21:38:23.90 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=141
21:38:25.66 Mixer 0 on at 450 rpm
21:39:27.72 Mixer 0 off
21:39:28.05 4 Empty RV48 for 1.500 minute(s) SynthPos=142
21:40:56.48 5 Repeat from step 2, 3 times SynthPos=143
21:40:57.80 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=144
21:40:57.96 Washing with DMF (B) 3.00ml per vessel to RV48
21:41:07.91 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=145
21:41:09.66 Mixer 0 on at 450 rpm
21:42:11.18 Mixer 0 off
21:42:11.56 4 Empty RV48 for 1.500 minute(s) SynthPos=146
21:43:39.44 5 Repeat from step 2, 3 times SynthPos=147
21:43:40.76 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=148
21:43:40.93 Washing with DMF (B) 3.00ml per vessel to RV48
21:43:50.87 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=149
21:43:52.63 Mixer 0 on at 450 rpm
21:44:54.03 Mixer 0 off
21:44:54.36 4 Empty RV48 for 1.500 minute(s) SynthPos=150
21:46:22.46 5 Repeat from step 2, 3 times SynthPos=151
21:46:23.78 6 Return SynthPos=152
21:46:24.17 28 REM HBTU48 SynthPos=153
21:46:24.50 29 Dispense Sequence SNI143.dsp with 0.699ml to RV48 rack using DMF
(1) SynthPos=154
21:46:24.50 Dispensing from Rack 4x7 vessel 10 to Rack RV48 vessel 11
21:46:26.42 Pick up 4000 microL and 0 steps
21:46:30.59 A1200R
21:46:44.93 Pick up 110 microL and 0 steps
21:46:45.64 A33R
21:46:46.03 Dispense 99 microL and 0 steps
21:46:46.03 A30R
21:46:48.88 --Cleaned Probe with 4000µl of DMF (1)
21:46:49.60 Pick up 110 microL and 0 steps
21:46:49.98 A33R
21:46:50.37 Dispense 99 microL and 0 steps
21:46:50.37 A30R
21:46:55.86 Pick up 924 microL and 0 steps
21:46:58.66 A277R
21:47:02.28 Dispense 823 microL and 0 steps
21:47:02.28 A247R
21:47:08.38 --Aspirated 698µl from 4x7[10](Leu)
21:47:10.41 Dispense 0 microL and 0 steps
21:47:10.41 A0R
21:47:15.80 --Dispensed 823µl to RV48[11]
21:47:19.09 30 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using
DMF (1) SynthPos=155
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21:47:19.09 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
21:47:19.09 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
21:47:21.01 Pick up 2250 microL and 0 steps
21:47:23.43 A675R
21:47:36.01 Pick up 110 microL and 0 steps
21:47:36.72 A33R
21:47:37.11 Dispense 99 microL and 0 steps
21:47:37.11 A30R
21:47:40.02 --Cleaned Probe with 2250µl of DMF (1)
21:47:40.68 Pick up 110 microL and 0 steps
21:47:41.06 A33R
21:47:41.45 Dispense 99 microL and 0 steps
21:47:41.45 A30R
21:47:47.87 Pick up 924 microL and 0 steps
21:47:50.67 A277R
21:47:54.52 Dispense 823 microL and 0 steps
21:47:54.52 A247R
21:48:00.84 --Aspirated 698µl from HBTU-350mL[1](HCTU)
21:48:03.09 Dispense 124 microL and 0 steps
21:48:03.09 A37R
21:48:08.25 --Dispensed 700µl to RV48[11]
21:48:08.69 Dispense 0 microL and 0 steps
21:48:08.69 A0R
21:48:12.97 --Dispensed 123µl to RV48[11]
21:48:16.27 31 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using
DMF (1) SynthPos=156
21:48:16.27 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
21:48:16.32 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
21:48:18.19 Pick up 2250 microL and 0 steps
21:48:20.61 A675R
21:48:33.19 Pick up 110 microL and 0 steps
21:48:33.96 A33R
21:48:34.28 Dispense 99 microL and 0 steps
21:48:34.28 A30R
21:48:37.20 --Cleaned Probe with 2250µl of DMF (1)
21:48:37.86 Pick up 110 microL and 0 steps
21:48:38.29 A33R
21:48:38.62 Dispense 99 microL and 0 steps
21:48:38.62 A30R
21:48:44.83 Pick up 924 microL and 0 steps
21:48:47.63 A277R
21:48:51.42 Dispense 823 microL and 0 steps
21:48:51.42 A247R
21:48:57.74 --Aspirated 698µl from DIEA-350mL[1](DIPEA)
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21:48:59.99
21:48:59.99
21:49:05.21
21:49:05.65
21:49:05.65
21:49:09.99
21:49:13.28
21:49:15.04
22:34:18.47
22:34:18.80
22:35:46.46
22:35:47.78
22:35:48.17
22:36:19.20
22:36:29.14
22:36:30.90
22:37:32.30
22:37:32.63
22:39:00.46
22:39:01.78
22:39:01.94
22:39:11.88
22:39:13.64
22:40:16.48
22:40:16.81
22:41:44.47
22:41:45.79
22:41:45.95
22:41:55.89
22:41:57.65
22:42:59.17
22:42:59.50
22:44:27.49
22:44:28.80
22:44:28.97
22:44:38.91
22:44:40.67
22:45:43.01
22:45:43.34
22:47:11.44
22:47:12.76
22:47:13.14
22:47:13.47
22:47:14.95
22:47:16.27

Dispense 124 microL and 0 steps
A37R
--Dispensed 700µl to RV48[11]
Dispense 0 microL and 0 steps
A0R
--Dispensed 123µl to RV48[11]
32 Mix "RV48" for 45.00 minutes at 450 rpm(s) and wait. SynthPos=157
Mixer 0 on at 450 rpm
Mixer 0 off
33 Empty RV48 for 1.500 minute(s) SynthPos=158
34 Goto ChemFile washcp48.cht, line 1 SynthPos=159
1 REM Wash after Coupling SynthPos=160
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=161
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=162
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=163
5 Repeat from step 2, 3 times SynthPos=164
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=165
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=166
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=167
5 Repeat from step 2, 3 times SynthPos=168
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=169
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=170
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=171
5 Repeat from step 2, 3 times SynthPos=172
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=173
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=174
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=175
5 Repeat from step 2, 3 times SynthPos=176
6 Return SynthPos=177
35 REM ** This is the data for cycle 4. ** SynthPos=178
36 <Set Active> SynthPos=179
37 Goto ChemFile depro48.cht, line 1 SynthPos=180
1 REM FMOC DEPROTECTION SynthPos=181
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22:47:16.60 2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
SynthPos=182
22:47:16.60 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
22:47:16.66 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
22:47:18.52 Pick up 2250 microL and 0 steps
22:47:21.00 A675R
22:47:33.52 Pick up 110 microL and 0 steps
22:47:34.29 A33R
22:47:34.67 Dispense 99 microL and 0 steps
22:47:34.67 A30R
22:47:37.53 --Cleaned Probe with 2250µl of DMF (1)
22:47:38.24 Pick up 110 microL and 0 steps
22:47:38.63 A33R
22:47:39.01 Dispense 99 microL and 0 steps
22:47:39.01 A30R
22:47:45.00 Pick up 2225 microL and 0 steps
22:47:51.70 A668R
22:47:55.49 Dispense 2126 microL and 0 steps
22:47:55.49 A638R
22:48:01.81 --Aspirated 2001µl from Pip-350mL[1](PIP)
22:48:04.06 Dispense 126 microL and 0 steps
22:48:04.06 A38R
22:48:11.20 --Dispensed 2000µl to RV48[11]
22:48:11.58 Dispense 1 microL and 0 steps
22:48:11.58 A0R
22:48:15.92 --Dispensed 126µl to RV48[11]
22:48:19.22 3 Mix "RV48" for 3.00 minutes at 450 rpm(s) and wait. SynthPos=183
22:48:20.97 Mixer 0 on at 450 rpm
22:51:22.28 Mixer 0 off
22:51:22.67 4 Empty RV48 for 1.500 minute(s) SynthPos=184
22:52:50.44 5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
SynthPos=185
22:52:50.44 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
22:52:50.44 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
22:52:51.15 Pick up 110 microL and 0 steps
22:52:51.87 A33R
22:52:52.25 Dispense 99 microL and 0 steps
22:52:52.25 A30R
22:52:58.24 Pick up 2225 microL and 0 steps
22:53:04.94 A668R
22:53:08.73 Dispense 2126 microL and 0 steps
22:53:08.73 A638R
22:53:14.88 --Aspirated 2001µl from Pip-350mL[1](PIP)
22:53:17.08 Dispense 126 microL and 0 steps
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22:53:17.08 A38R
22:53:24.22 --Dispensed 2000µl to RV48[11]
22:53:24.66 Dispense 1 microL and 0 steps
22:53:24.66 A0R
22:53:28.94 --Dispensed 126µl to RV48[11]
22:53:32.24 6 Mix "RV48" for 8.00 minutes at 450 rpm(s) and wait. SynthPos=186
22:53:34.05 Mixer 0 on at 450 rpm
23:01:36.57 Mixer 0 off
23:01:36.90 7 Empty RV48 for 1.500 minute(s) SynthPos=187
23:03:05.44 8 Return SynthPos=188
23:03:05.77 38 Goto ChemFile washdp48.cht, line 1 SynthPos=189
23:03:07.14 1 REM Wash after Deprotection SynthPos=190
23:03:07.47 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=191
23:03:38.50 Washing with DMF (B) 3.00ml per vessel to RV48
23:03:48.45 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=192
23:03:50.20 Mixer 0 on at 450 rpm
23:04:52.43 Mixer 0 off
23:04:52.76 4 Empty RV48 for 1.500 minute(s) SynthPos=193
23:06:20.48 5 Repeat from step 2, 3 times SynthPos=194
23:06:21.80 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=195
23:06:21.96 Washing with DMF (B) 3.00ml per vessel to RV48
23:06:31.85 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=196
23:06:33.66 Mixer 0 on at 450 rpm
23:07:35.29 Mixer 0 off
23:07:35.67 4 Empty RV48 for 1.500 minute(s) SynthPos=197
23:09:03.44 5 Repeat from step 2, 3 times SynthPos=198
23:09:04.76 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=199
23:09:04.93 Washing with DMF (B) 3.00ml per vessel to RV48
23:09:14.87 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=200
23:09:16.63 Mixer 0 on at 450 rpm
23:10:18.25 Mixer 0 off
23:10:18.58 4 Empty RV48 for 1.500 minute(s) SynthPos=201
23:11:46.46 5 Repeat from step 2, 3 times SynthPos=202
23:11:47.78 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=203
23:11:47.95 Washing with DMF (B) 3.00ml per vessel to RV48
23:11:57.83 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=204
23:11:59.65 Mixer 0 on at 450 rpm
23:13:01.44 Mixer 0 off
23:13:01.77 4 Empty RV48 for 1.500 minute(s) SynthPos=205
23:14:29.48 5 Repeat from step 2, 3 times SynthPos=206
23:14:30.80 6 Return SynthPos=207
23:14:31.18 39 REM HBTU48 SynthPos=208
23:14:31.51 40 Dispense Sequence SNI144.dsp with 0.699ml to RV48 rack using DMF
(1) SynthPos=209
23:14:31.51 Dispensing from Rack 4x7 vessel 13 to Rack RV48 vessel 11
23:14:33.44 Pick up 4000 microL and 0 steps
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23:14:37.61 A1200R
23:14:51.95 Pick up 110 microL and 0 steps
23:14:52.72 A33R
23:14:53.04 Dispense 99 microL and 0 steps
23:14:53.04 A30R
23:14:55.96 --Cleaned Probe with 4000µl of DMF (1)
23:14:56.67 Pick up 110 microL and 0 steps
23:14:57.05 A33R
23:14:57.38 Dispense 99 microL and 0 steps
23:14:57.38 A30R
23:15:02.99 Pick up 924 microL and 0 steps
23:15:05.79 A277R
23:15:09.47 Dispense 823 microL and 0 steps
23:15:09.47 A247R
23:15:15.56 --Aspirated 698µl from 4x7[13](Phe)
23:15:17.49 Dispense 0 microL and 0 steps
23:15:17.49 A0R
23:15:22.81 --Dispensed 823µl to RV48[11]
23:15:26.11 41 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using
DMF (1) SynthPos=210
23:15:26.11 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
23:15:26.11 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
23:15:28.03 Pick up 2250 microL and 0 steps
23:15:30.45 A675R
23:15:42.97 Pick up 110 microL and 0 steps
23:15:43.74 A33R
23:15:44.13 Dispense 99 microL and 0 steps
23:15:44.13 A30R
23:15:46.98 --Cleaned Probe with 2250µl of DMF (1)
23:15:47.70 Pick up 110 microL and 0 steps
23:15:48.08 A33R
23:15:48.46 Dispense 99 microL and 0 steps
23:15:48.46 A30R
23:15:54.89 Pick up 924 microL and 0 steps
23:15:57.64 A277R
23:16:01.48 Dispense 823 microL and 0 steps
23:16:01.48 A247R
23:16:07.80 --Aspirated 698µl from HBTU-350mL[1](HCTU)
23:16:10.05 Dispense 124 microL and 0 steps
23:16:10.05 A37R
23:16:15.27 --Dispensed 700µl to RV48[11]
23:16:15.65 Dispense 0 microL and 0 steps
23:16:15.65 A0R
23:16:19.99 --Dispensed 123µl to RV48[11]
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23:16:23.23 42 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using
DMF (1) SynthPos=211
23:16:23.23 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
23:16:23.29 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
23:16:25.15 Pick up 2250 microL and 0 steps
23:16:27.63 A675R
23:16:40.15 Pick up 110 microL and 0 steps
23:16:40.92 A33R
23:16:41.25 Dispense 99 microL and 0 steps
23:16:41.25 A30R
23:16:44.16 --Cleaned Probe with 2250µl of DMF (1)
23:16:44.82 Pick up 110 microL and 0 steps
23:16:45.26 A33R
23:16:45.59 Dispense 99 microL and 0 steps
23:16:45.59 A30R
23:16:51.79 Pick up 924 microL and 0 steps
23:16:54.59 A277R
23:16:58.38 Dispense 823 microL and 0 steps
23:16:58.38 A247R
23:17:04.76 --Aspirated 698µl from DIEA-350mL[1](DIPEA)
23:17:06.95 Dispense 124 microL and 0 steps
23:17:06.95 A37R
23:17:12.17 --Dispensed 700µl to RV48[11]
23:17:12.56 Dispense 0 microL and 0 steps
23:17:12.56 A0R
23:17:16.89 --Dispensed 123µl to RV48[11]
23:17:20.19 43 Mix "RV48" for 45.00 minutes at 450 rpm(s) and wait. SynthPos=212
23:17:21.95 Mixer 0 on at 450 rpm
00:02:23.30 Mixer 0 off
00:02:23.63 44 Empty RV48 for 1.500 minute(s) SynthPos=213
00:03:51.45 45 Goto ChemFile washcp48.cht, line 1 SynthPos=214
00:03:52.77 1 REM Wash after Coupling SynthPos=215
00:03:53.15 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=216
00:04:24.19 Washing with DMF (A) 3.00ml per vessel to RV48
00:04:34.13 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=217
00:04:35.89 Mixer 0 on at 450 rpm
00:05:37.40 Mixer 0 off
00:05:37.73 4 Empty RV48 for 1.500 minute(s) SynthPos=218
00:07:05.45 5 Repeat from step 2, 3 times SynthPos=219
00:07:06.77 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=220
00:07:06.93 Washing with DMF (A) 3.00ml per vessel to RV48
00:07:16.87 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=221
00:07:18.63 Mixer 0 on at 450 rpm
00:08:19.98 Mixer 0 off
00:08:20.31 4 Empty RV48 for 1.500 minute(s) SynthPos=222
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00:09:48.47 5 Repeat from step 2, 3 times SynthPos=223
00:09:49.78 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=224
00:09:49.95 Washing with DMF (A) 3.00ml per vessel to RV48
00:09:59.89 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=225
00:10:01.65 Mixer 0 on at 450 rpm
00:11:03.55 Mixer 0 off
00:11:03.88 4 Empty RV48 for 1.500 minute(s) SynthPos=226
00:12:31.49 5 Repeat from step 2, 3 times SynthPos=227
00:12:32.80 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=228
00:12:32.97 Washing with DMF (A) 3.00ml per vessel to RV48
00:12:42.91 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=229
00:12:44.67 Mixer 0 on at 450 rpm
00:13:46.35 Mixer 0 off
00:13:46.68 4 Empty RV48 for 1.500 minute(s) SynthPos=230
00:15:14.45 5 Repeat from step 2, 3 times SynthPos=231
00:15:15.77 6 Return SynthPos=232
00:15:16.15 46 REM ** This is the data for cycle 5. ** SynthPos=233
00:15:16.48 47 <Set Active> SynthPos=234
00:15:17.96 48 Goto ChemFile depro48.cht, line 1 SynthPos=235
00:15:19.28 1 REM FMOC DEPROTECTION SynthPos=236
00:15:19.67 2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
SynthPos=237
00:15:19.67 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
00:15:19.67 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
00:15:21.59 Pick up 2250 microL and 0 steps
00:15:24.01 A675R
00:15:36.53 Pick up 110 microL and 0 steps
00:15:37.30 A33R
00:15:37.63 Dispense 99 microL and 0 steps
00:15:37.63 A30R
00:15:40.54 --Cleaned Probe with 2250µl of DMF (1)
00:15:41.25 Pick up 110 microL and 0 steps
00:15:41.64 A33R
00:15:42.02 Dispense 99 microL and 0 steps
00:15:42.02 A30R
00:15:48.01 Pick up 2225 microL and 0 steps
00:15:54.71 A668R
00:15:58.50 Dispense 2126 microL and 0 steps
00:15:58.50 A638R
00:16:04.87 --Aspirated 2001µl from Pip-350mL[1](PIP)
00:16:07.07 Dispense 126 microL and 0 steps
00:16:07.07 A38R
00:16:14.21 --Dispensed 2000µl to RV48[11]
00:16:14.65 Dispense 1 microL and 0 steps
00:16:14.65 A0R
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00:16:18.93 --Dispensed 126µl to RV48[11]
00:16:22.23 3 Mix "RV48" for 3.00 minutes at 450 rpm(s) and wait. SynthPos=238
00:16:24.04 Mixer 0 on at 450 rpm
00:19:26.28 Mixer 0 off
00:19:26.61 4 Empty RV48 for 1.500 minute(s) SynthPos=239
00:20:54.44 5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
SynthPos=240
00:20:54.44 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
00:20:54.44 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
00:20:55.10 Pick up 110 microL and 0 steps
00:20:55.87 A33R
00:20:56.25 Dispense 99 microL and 0 steps
00:20:56.25 A30R
00:21:02.24 Pick up 2225 microL and 0 steps
00:21:08.94 A668R
00:21:12.73 Dispense 2126 microL and 0 steps
00:21:12.73 A638R
00:21:18.88 --Aspirated 2001µl from Pip-350mL[1](PIP)
00:21:21.08 Dispense 126 microL and 0 steps
00:21:21.08 A38R
00:21:28.22 --Dispensed 2000µl to RV48[11]
00:21:28.66 Dispense 1 microL and 0 steps
00:21:28.66 A0R
00:21:32.94 --Dispensed 126µl to RV48[11]
00:21:36.24 6 Mix "RV48" for 8.00 minutes at 450 rpm(s) and wait. SynthPos=241
00:21:38.05 Mixer 0 on at 450 rpm
00:29:41.01 Mixer 0 off
00:29:41.34 7 Empty RV48 for 1.500 minute(s) SynthPos=242
00:31:09.44 8 Return SynthPos=243
00:31:09.77 49 Goto ChemFile washdp48.cht, line 1 SynthPos=244
00:31:11.09 1 REM Wash after Deprotection SynthPos=245
00:31:11.47 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=246
00:31:42.50 Washing with DMF (B) 3.00ml per vessel to RV48
00:31:52.45 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=247
00:31:54.20 Mixer 0 on at 450 rpm
00:32:56.65 Mixer 0 off
00:32:57.04 4 Empty RV48 for 1.500 minute(s) SynthPos=248
00:34:25.47 5 Repeat from step 2, 3 times SynthPos=249
00:34:26.79 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=250
00:34:26.95 Washing with DMF (B) 3.00ml per vessel to RV48
00:34:36.84 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=251
00:34:38.65 Mixer 0 on at 450 rpm
00:35:40.28 Mixer 0 off
00:35:40.61 4 Empty RV48 for 1.500 minute(s) SynthPos=252
00:37:08.49 5 Repeat from step 2, 3 times SynthPos=253
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00:37:09.81 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=254
00:37:09.97 Washing with DMF (B) 3.00ml per vessel to RV48
00:37:19.91 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=255
00:37:21.67 Mixer 0 on at 450 rpm
00:38:23.24 Mixer 0 off
00:38:23.57 4 Empty RV48 for 1.500 minute(s) SynthPos=256
00:39:51.45 5 Repeat from step 2, 3 times SynthPos=257
00:39:52.77 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=258
00:39:52.93 Washing with DMF (B) 3.00ml per vessel to RV48
00:40:02.88 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=259
00:40:04.63 Mixer 0 on at 450 rpm
00:41:06.15 Mixer 0 off
00:41:06.48 4 Empty RV48 for 1.500 minute(s) SynthPos=260
00:42:34.47 5 Repeat from step 2, 3 times SynthPos=261
00:42:35.79 6 Return SynthPos=262
00:42:36.17 50 REM HBTU48 SynthPos=263
00:42:36.50 51 Dispense Sequence SNI145.dsp with 0.699ml to RV48 rack using DMF
(1) SynthPos=264
00:42:36.50 Dispensing from Rack 4x7 vessel 10 to Rack RV48 vessel 11
00:42:38.42 Pick up 4000 microL and 0 steps
00:42:42.60 A1200R
00:42:56.93 Pick up 110 microL and 0 steps
00:42:57.70 A33R
00:42:58.03 Dispense 99 microL and 0 steps
00:42:58.03 A30R
00:43:00.94 --Cleaned Probe with 4000µl of DMF (1)
00:43:01.60 Pick up 110 microL and 0 steps
00:43:02.04 A33R
00:43:02.37 Dispense 99 microL and 0 steps
00:43:02.37 A30R
00:43:07.86 Pick up 924 microL and 0 steps
00:43:10.67 A277R
00:43:14.29 Dispense 823 microL and 0 steps
00:43:14.29 A247R
00:43:20.44 --Aspirated 698µl from 4x7[10](Leu)
00:43:22.47 Dispense 0 microL and 0 steps
00:43:22.47 A0R
00:43:27.86 --Dispensed 823µl to RV48[11]
00:43:31.10 52 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using
DMF (1) SynthPos=265
00:43:31.10 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
00:43:31.10 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
00:43:33.02 Pick up 2250 microL and 0 steps
00:43:35.44 A675R
00:43:48.02 Pick up 110 microL and 0 steps
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00:43:48.78 A33R
00:43:49.11 Dispense 99 microL and 0 steps
00:43:49.11 A30R
00:43:52.02 --Cleaned Probe with 2250µl of DMF (1)
00:43:52.68 Pick up 110 microL and 0 steps
00:43:53.12 A33R
00:43:53.45 Dispense 99 microL and 0 steps
00:43:53.45 A30R
00:43:59.88 Pick up 924 microL and 0 steps
00:44:02.68 A277R
00:44:06.47 Dispense 823 microL and 0 steps
00:44:06.47 A247R
00:44:12.79 --Aspirated 698µl from HBTU-350mL[1](HCTU)
00:44:15.04 Dispense 124 microL and 0 steps
00:44:15.04 A37R
00:44:20.26 --Dispensed 700µl to RV48[11]
00:44:20.64 Dispense 0 microL and 0 steps
00:44:20.64 A0R
00:44:24.98 --Dispensed 123µl to RV48[11]
00:44:28.28 53 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using
DMF (1) SynthPos=266
00:44:28.28 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
00:44:28.28 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
00:44:30.14 Pick up 2250 microL and 0 steps
00:44:32.61 A675R
00:44:45.14 Pick up 110 microL and 0 steps
00:44:45.91 A33R
00:44:46.24 Dispense 99 microL and 0 steps
00:44:46.24 A30R
00:44:49.15 --Cleaned Probe with 2250µl of DMF (1)
00:44:49.81 Pick up 110 microL and 0 steps
00:44:50.25 A33R
00:44:50.58 Dispense 99 microL and 0 steps
00:44:50.58 A30R
00:44:56.78 Pick up 924 microL and 0 steps
00:44:59.58 A277R
00:45:03.43 Dispense 823 microL and 0 steps
00:45:03.43 A247R
00:45:09.74 --Aspirated 698µl from DIEA-350mL[1](DIPEA)
00:45:12.00 Dispense 124 microL and 0 steps
00:45:12.00 A37R
00:45:17.16 --Dispensed 700µl to RV48[11]
00:45:17.60 Dispense 0 microL and 0 steps
00:45:17.60 A0R
00:45:21.88 --Dispensed 123µl to RV48[11]
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00:45:25.18 54 Mix "RV48" for 45.00 minutes at 450 rpm(s) and wait. SynthPos=267
00:45:26.99 Mixer 0 on at 450 rpm
01:30:28.28 Mixer 0 off
01:30:28.61 55 Empty RV48 for 1.500 minute(s) SynthPos=268
01:31:56.44 56 Goto ChemFile washcp48.cht, line 1 SynthPos=269
01:31:57.76 1 REM Wash after Coupling SynthPos=270
01:31:58.14 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=271
01:32:29.17 Washing with DMF (A) 3.00ml per vessel to RV48
01:32:39.11 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=272
01:32:40.87 Mixer 0 on at 450 rpm
01:33:42.22 Mixer 0 off
01:33:42.55 4 Empty RV48 for 1.500 minute(s) SynthPos=273
01:35:10.49 5 Repeat from step 2, 3 times SynthPos=274
01:35:11.81 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=275
01:35:11.97 Washing with DMF (A) 3.00ml per vessel to RV48
01:35:21.91 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=276
01:35:23.67 Mixer 0 on at 450 rpm
01:36:25.08 Mixer 0 off
01:36:25.41 4 Empty RV48 for 1.500 minute(s) SynthPos=277
01:37:53.45 5 Repeat from step 2, 3 times SynthPos=278
01:37:54.77 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=279
01:37:54.94 Washing with DMF (A) 3.00ml per vessel to RV48
01:38:04.88 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=280
01:38:06.63 Mixer 0 on at 450 rpm
01:39:07.77 Mixer 0 off
01:39:08.10 4 Empty RV48 for 1.500 minute(s) SynthPos=281
01:40:36.47 5 Repeat from step 2, 3 times SynthPos=282
01:40:37.79 2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=283
01:40:37.95 Washing with DMF (A) 3.00ml per vessel to RV48
01:40:47.90 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=284
01:40:49.65 Mixer 0 on at 450 rpm
01:41:51.44 Mixer 0 off
01:41:51.77 4 Empty RV48 for 1.500 minute(s) SynthPos=285
01:43:19.44 5 Repeat from step 2, 3 times SynthPos=286
01:43:20.75 6 Return SynthPos=287
01:43:21.14 57 REM ** This is the data for cycle 6. ** SynthPos=288
01:43:21.47 58 <Set Active> SynthPos=289
01:43:22.95 59 Goto ChemFile depro48.cht, line 1 SynthPos=290
01:43:24.27 1 REM FMOC DEPROTECTION SynthPos=291
01:43:24.65 2 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
SynthPos=292
01:43:24.65 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
01:43:24.65 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
01:43:26.52 Pick up 2250 microL and 0 steps
01:43:28.99 A675R
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01:43:41.52 Pick up 110 microL and 0 steps
01:43:42.28 A33R
01:43:42.67 Dispense 99 microL and 0 steps
01:43:42.67 A30R
01:43:45.53 --Cleaned Probe with 2250µl of DMF (1)
01:43:46.24 Pick up 110 microL and 0 steps
01:43:46.68 A33R
01:43:47.01 Dispense 99 microL and 0 steps
01:43:47.01 A30R
01:43:52.99 Pick up 2225 microL and 0 steps
01:43:59.70 A668R
01:44:03.49 Dispense 2126 microL and 0 steps
01:44:03.49 A638R
01:44:09.86 --Aspirated 2001µl from Pip-350mL[1](PIP)
01:44:12.05 Dispense 126 microL and 0 steps
01:44:12.05 A38R
01:44:19.19 --Dispensed 2000µl to RV48[11]
01:44:19.58 Dispense 1 microL and 0 steps
01:44:19.58 A0R
01:44:23.92 --Dispensed 126µl to RV48[11]
01:44:27.21 3 Mix "RV48" for 3.00 minutes at 450 rpm(s) and wait. SynthPos=293
01:44:28.97 Mixer 0 on at 450 rpm
01:47:30.28 Mixer 0 off
01:47:30.66 4 Empty RV48 for 1.500 minute(s) SynthPos=294
01:48:58.44 5 Transfer 2.00ml from Pip-350mL[1](PIP) to RV48[1-48] using DMF (1)
SynthPos=295
01:48:58.44 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
01:48:58.44 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
01:48:59.09 Pick up 110 microL and 0 steps
01:48:59.86 A33R
01:49:00.25 Dispense 99 microL and 0 steps
01:49:00.25 A30R
01:49:06.23 Pick up 2225 microL and 0 steps
01:49:12.94 A668R
01:49:16.73 Dispense 2126 microL and 0 steps
01:49:16.73 A638R
01:49:22.88 --Aspirated 2001µl from Pip-350mL[1](PIP)
01:49:25.07 Dispense 126 microL and 0 steps
01:49:25.07 A38R
01:49:32.21 --Dispensed 2000µl to RV48[11]
01:49:32.65 Dispense 1 microL and 0 steps
01:49:32.65 A0R
01:49:36.94 --Dispensed 126µl to RV48[11]
01:49:40.23 6 Mix "RV48" for 8.00 minutes at 450 rpm(s) and wait. SynthPos=296
01:49:42.05 Mixer 0 on at 450 rpm
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01:57:44.62 Mixer 0 off
01:57:45.01 7 Empty RV48 for 1.500 minute(s) SynthPos=297
01:59:13.44 8 Return SynthPos=298
01:59:13.77 60 Goto ChemFile washdp48.cht, line 1 SynthPos=299
01:59:15.14 1 REM Wash after Deprotection SynthPos=300
01:59:15.47 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=301
01:59:46.50 Washing with DMF (B) 3.00ml per vessel to RV48
01:59:56.44 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=302
01:59:58.20 Mixer 0 on at 450 rpm
02:01:00.32 Mixer 0 off
02:01:00.65 4 Empty RV48 for 1.500 minute(s) SynthPos=303
02:02:28.48 5 Repeat from step 2, 3 times SynthPos=304
02:02:29.79 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=305
02:02:29.96 Washing with DMF (B) 3.00ml per vessel to RV48
02:02:39.90 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=306
02:02:41.66 Mixer 0 on at 450 rpm
02:03:43.18 Mixer 0 off
02:03:43.50 4 Empty RV48 for 1.500 minute(s) SynthPos=307
02:05:11.44 5 Repeat from step 2, 3 times SynthPos=308
02:05:12.76 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=309
02:05:12.92 Washing with DMF (B) 3.00ml per vessel to RV48
02:05:22.87 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=310
02:05:24.62 Mixer 0 on at 450 rpm
02:06:26.14 Mixer 0 off
02:06:26.52 4 Empty RV48 for 1.500 minute(s) SynthPos=311
02:07:54.46 5 Repeat from step 2, 3 times SynthPos=312
02:07:55.78 2 Fast Wash using System Fluid DMF (B) 3.00ml to RV48 SynthPos=313
02:07:55.94 Washing with DMF (B) 3.00ml per vessel to RV48
02:08:05.83 3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=314
02:08:07.64 Mixer 0 on at 450 rpm
02:09:09.82 Mixer 0 off
02:09:10.15 4 Empty RV48 for 1.500 minute(s) SynthPos=315
02:10:38.47 5 Repeat from step 2, 3 times SynthPos=316
02:10:39.79 6 Return SynthPos=317
02:10:40.17 61 REM HBTU48 SynthPos=318
02:10:40.50 62 Dispense Sequence SNI146.dsp with 0.699ml to RV48 rack using DMF
(1) SynthPos=319
02:10:40.50 Dispensing from Rack 4x7 vessel 13 to Rack RV48 vessel 11
02:10:42.42 Pick up 4000 microL and 0 steps
02:10:46.60 A1200R
02:11:00.93 Pick up 110 microL and 0 steps
02:11:01.70 A33R
02:11:02.03 Dispense 99 microL and 0 steps
02:11:02.03 A30R
02:11:04.94 --Cleaned Probe with 4000µl of DMF (1)
02:11:05.66 Pick up 110 microL and 0 steps
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02:11:06.04 A33R
02:11:06.37 Dispense 99 microL and 0 steps
02:11:06.37 A30R
02:11:12.03 Pick up 924 microL and 0 steps
02:11:14.77 A277R
02:11:18.45 Dispense 823 microL and 0 steps
02:11:18.45 A247R
02:11:24.55 --Aspirated 698µl from 4x7[13](Phe)
02:11:26.47 Dispense 0 microL and 0 steps
02:11:26.47 A0R
02:11:31.80 --Dispensed 823µl to RV48[11]
02:11:35.10 63 Transfer 0.70ml from HBTU-350mL[1](HCTU) to RV48[1-48] using
DMF (1) SynthPos=320
02:11:35.10 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…
02:11:35.10 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
02:11:37.02 Pick up 2250 microL and 0 steps
02:11:39.43 A675R
02:11:51.96 Pick up 110 microL and 0 steps
02:11:52.73 A33R
02:11:53.11 Dispense 99 microL and 0 steps
02:11:53.11 A30R
02:11:55.97 --Cleaned Probe with 2250µl of DMF (1)
02:11:56.68 Pick up 110 microL and 0 steps
02:11:57.07 A33R
02:11:57.45 Dispense 99 microL and 0 steps
02:11:57.45 A30R
02:12:03.88 Pick up 924 microL and 0 steps
02:12:06.68 A277R
02:12:10.52 Dispense 823 microL and 0 steps
02:12:10.52 A247R
02:12:16.84 --Aspirated 698µl from HBTU-350mL[1](HCTU)
02:12:19.04 Dispense 124 microL and 0 steps
02:12:19.04 A37R
02:12:24.25 --Dispensed 700µl to RV48[11]
02:12:24.69 Dispense 0 microL and 0 steps
02:12:24.69 A0R
02:12:28.98 --Dispensed 123µl to RV48[11]
02:12:32.27 64 Transfer 0.70ml from DIEA-350mL[1](DIPEA) to RV48[1-48] using
DMF (1) SynthPos=321
02:12:32.27 RV48 : Vessel 0 DEACTIVE -- VesselsLeft 47
…7
02:12:32.27 RV48 : Vessel 47 DEACTIVE -- VesselsLeft 1
02:12:34.20 Pick up 2250 microL and 0 steps
02:12:36.61 A675R
02:12:49.19 Pick up 110 microL and 0 steps
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02:12:49.90
02:12:50.29
02:12:50.29
02:12:53.14
02:12:53.86
02:12:54.24
02:12:54.63
02:12:54.63
02:13:00.83
02:13:03.64
02:13:07.43
02:13:07.43
02:13:13.80
02:13:15.99
02:13:15.99
02:13:21.21
02:13:21.65
02:13:21.65
02:13:25.93
02:13:29.23
02:13:30.99
02:58:32.44
02:58:32.77
03:00:00.49
03:00:01.81
03:00:02.19
03:00:33.22
03:00:43.17
03:00:44.92
03:01:46.71
03:01:47.04
03:03:15.47
03:03:16.79
03:03:16.96
03:03:26.90
03:03:28.66
03:04:29.90
03:04:30.28
03:05:58.44
03:05:59.76
03:05:59.92
03:06:09.86
03:06:11.62
03:07:13.52
03:07:13.91
03:08:42.45

A33R
Dispense 99 microL and 0 steps
A30R
--Cleaned Probe with 2250µl of DMF (1)
Pick up 110 microL and 0 steps
A33R
Dispense 99 microL and 0 steps
A30R
Pick up 924 microL and 0 steps
A277R
Dispense 823 microL and 0 steps
A247R
--Aspirated 698µl from DIEA-350mL[1](DIPEA)
Dispense 124 microL and 0 steps
A37R
--Dispensed 700µl to RV48[11]
Dispense 0 microL and 0 steps
A0R
--Dispensed 123µl to RV48[11]
65 Mix "RV48" for 45.00 minutes at 450 rpm(s) and wait. SynthPos=322
Mixer 0 on at 450 rpm
Mixer 0 off
66 Empty RV48 for 1.500 minute(s) SynthPos=323
67 Goto ChemFile washcp48.cht, line 1 SynthPos=324
1 REM Wash after Coupling SynthPos=325
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=326
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=327
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=328
5 Repeat from step 2, 3 times SynthPos=329
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=330
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=331
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=332
5 Repeat from step 2, 3 times SynthPos=333
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=334
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=335
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=336
5 Repeat from step 2, 3 times SynthPos=337
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03:08:43.76
03:08:43.93
03:08:53.87
03:08:55.63
03:09:57.64
03:09:58.02
03:11:26.45
03:11:27.77
03:11:28.16
03:11:29.47
03:11:30.79
03:11:31.18
03:11:31.34
03:11:41.23
03:11:43.04
03:12:45.93
03:12:46.26
03:14:14.47
03:14:15.79
03:14:15.95
03:14:25.90
03:14:27.65
03:15:29.83
03:15:30.16
03:16:58.48
03:16:59.80
03:16:59.96
03:17:09.90
03:17:11.66
03:18:13.62
03:18:13.95
03:19:42.49
03:19:43.80
03:19:43.97
03:19:53.91
03:19:55.67
03:20:57.18
03:20:57.57
03:22:25.45
03:22:26.77
03:22:27.15
03:22:29.07
03:22:38.30
03:22:49.18
03:22:58.35
03:23:19.11

2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=338
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=339
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=340
5 Repeat from step 2, 3 times SynthPos=341
6 Return SynthPos=342
68 Goto ChemFile washfn48.cht, line 1 SynthPos=343
1 Goto ChemFile C:\AAPPTEC\WASHCP48.CHM, line 1 SynthPos=344
1 REM Wash after Coupling SynthPos=345
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=346
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=347
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=348
5 Repeat from step 2, 3 times SynthPos=349
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=350
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=351
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=352
5 Repeat from step 2, 3 times SynthPos=353
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=354
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=355
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=356
5 Repeat from step 2, 3 times SynthPos=357
2 Fast Wash using System Fluid DMF (A) 3.00ml to RV48 SynthPos=358
Washing with DMF (A) 3.00ml per vessel to RV48
3 Mix "RV48" for 1.00 minutes at 450 rpm(s) and wait. SynthPos=359
Mixer 0 on at 450 rpm
Mixer 0 off
4 Empty RV48 for 1.500 minute(s) SynthPos=360
5 Repeat from step 2, 3 times SynthPos=361
6 Return SynthPos=362
2 Dispense System Fluid MEOH (2) 3.00ml to RV48[1-48] SynthPos=363
Pick up 9000 microL and 0 steps
A2700R
Pick up 9000 microL and 0 steps
A2700R
Pick up 40 microL and 0 steps
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03:23:19.61
03:23:20.81
03:23:20.81
03:23:23.73
03:23:24.06
03:23:27.19
03:23:27.84
03:23:31.31
03:23:31.31
03:23:40.37
03:23:43.22
03:23:45.26
03:25:47.25
03:25:47.58
03:28:45.48
03:28:46.80
03:28:47.18
03:28:50.37
03:28:50.97
03:28:54.49
03:28:54.49
03:29:03.49
03:29:06.41
03:29:08.44
03:31:11.69
03:31:12.02
03:34:10.47
03:34:11.79
03:34:12.18
03:34:15.36
03:34:15.97
03:34:19.48
03:34:19.48
03:34:28.54
03:34:31.40
03:34:33.43
03:36:35.37
03:36:35.75
03:39:33.44
03:39:34.75
03:44:32.45
03:44:39.81

A12R
Dispense 29 microL and 0 steps
A9R
--Cleaned Probe with 18000µl of MEOH (2)
Pick up 3000 microL and 0 steps
A900R
--Aspirated 2999µl of System Fluid MEOH (2)
Dispense 0 microL and 0 steps
A0R
--Dispensed 2999µl to RV48[11]
3 Mix "RV48" for 2.00 minutes at 475 rpm(s) and wait. SynthPos=364
Mixer 0 on at 475 rpm
Mixer 0 off
4 Empty RV48 for 3.000 minute(s) SynthPos=365
5 Repeat from step 2, 2 times SynthPos=366
2 Dispense System Fluid MEOH (2) 3.00ml to RV48[1-48] SynthPos=367
Pick up 3000 microL and 0 steps
A900R
--Aspirated 2999µl of System Fluid MEOH (2)
Dispense 0 microL and 0 steps
A0R
--Dispensed 2999µl to RV48[11]
3 Mix "RV48" for 2.00 minutes at 475 rpm(s) and wait. SynthPos=368
Mixer 0 on at 475 rpm
Mixer 0 off
4 Empty RV48 for 3.000 minute(s) SynthPos=369
5 Repeat from step 2, 2 times SynthPos=370
2 Dispense System Fluid MEOH (2) 3.00ml to RV48[1-48] SynthPos=371
Pick up 3000 microL and 0 steps
A900R
--Aspirated 2999µl of System Fluid MEOH (2)
Dispense 0 microL and 0 steps
A0R
--Dispensed 2999µl to RV48[11]
3 Mix "RV48" for 2.00 minutes at 475 rpm(s) and wait. SynthPos=372
Mixer 0 on at 475 rpm
Mixer 0 off
4 Empty RV48 for 3.000 minute(s) SynthPos=373
5 Repeat from step 2, 2 times SynthPos=374
6 Empty RV48 for 5.000 minute(s) SynthPos=375
7 Return SynthPos=376
Ending ChemFile - C:\AAPPTEC\SNI144.CHM
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